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1 Riassunto 
 
Sintesi Chimica ed Ingegnerizzazione di Citochine a Potenziale Interesse 
Terapeutico 
 
La recenti innovazioni nella sintesi chimica dei peptidi e delle tecniche di 
bioconiugazione hanno rilanciato nei primi anni novanta la sintesi chimica di polipetidi 
con catene superiori a 100 residui. Nel 1994, il gruppo del Prof. S. Kent ha descritto 
per la prima volta sulla rivista Science la ligazione di due peptidi non protetti in acqua 
a pH neutro, reazione che ha generato un solo polipeptide avente un legame 
ammidico nativo al sito di ligazione, tecnica chiamata Native Chemical Ligation 
(NCL). Native Chemical Ligation ha permesso negli anni seguenti la sintesisi chimica 
di diverse decine di polypeptidi e proteine di piccola e media taglia. In particolare nel 
2003 e’ stata presentata sulla rivista Science la sintesi chimica totale di SEP 
(Synthetic Eritropoietin Protein), molecola poi entrata in fase clinica I.  
In collaborazione con il Prof. C. Dinarello, Univerista’ del Colorado, Denver, si e’ 
deciso di intraprendere la sintesi chimica di due citokine di rilenvante interesse 
biologico e terapeutico: Interleukina 18 e Interleukina 32. 
 
H-IL-18 consta di 157 residui ed e’ una citokina proinfiammatoria che appartiene alla 
famiglia dei ligandi IL-1, inizialmente clonata come fattore di induzione di IFN-γ, ha 
un ruolo chiave in diverse patologie infiammatorie, allergiche ed autoimmunitarie. In 
particolare, Il-18 inducendo la produzione di IFN-γ da parte delle cellule T, e’ stata 
utilizzata con successo nella stimolazione della difesa immunitaria contro tumori in 
topi e dopo studi preclinici di tossicita’ su scimmie e’al momento in Clinical Trials per 
il trattamento di patologie tumorali. H-IL-18 ricombinante e’ sensibile all’ossidazione 
atmosferica ed e’ prona a formare dei prodotti di oligomerizzazione attraverso ponti 
disolfuro inter-molecolari che rendono la molecola inattiva. Data la rilevanza delle 
applicazioni mediche di h-IL-18, (in Clinical Trials per il trattamento di patologie 
tumorali ) esiste la necessità di trovare una forma stabile della proteina che possa 
garantirne un uso clinico per le diverse applicazioni.  
L’Interleukina IL-32 e’ una nuova Interleukina recentemente scoperta dal gruppo del 
Prof. C.Dinarello presso l’Universita’ del Colorado. Il-32 esiste in 4 differenti varianti. 
La sintesi dell’H-Il-32 e’ divenuta prioritaria  nello sviluppo del lavoro di tesi a causa 
della rilevanza scientifica che ha la proteina nei processi infiammatori e 
automminitari. La sintesi chimica a questo stadio della ricerca riveste un ruolo vitale 
nella conferma dei dati scientifici ottenuti precedentemente con materiale 
ricombinante a causa della difficolta’ nell’espressione della proteina, sia dal punto di 
vista della quantita’ del materiale prodotto sia dal punto di vista della purezza in 
particolare riguardo alla presenza di tossine o di altro materiale biologico 
potenzialmente bioattivo. Qualora infatti il polipeptide di sintesi riproducesse l’attivita’ 
biologica della proteina ricombinante confermerebbe l’esistenza di nuovi pathways 
infiammatori ed autoimmunitari.   H-Il-32 consiste di 164 residui. In collaborazione 
con il Prof. Dinarello, abbiamo sintetizzato la porzione N-terminale della proteina γ 
(gamma) isoform che a priori dovrebbe possedere attivita’ biologica analoga a quella 
umana. La parte N-terminale consiste di 103 residui con 4 cisteine e due ponti 
disolfuro. In base ai risultati biologici ottenuti, in un secondo momento eventualmente 
si pensera’ alla sintesi della proteina umana nella sua completezza. 
 
2 Obiettivi. 
1) H-IL-18 
Sintesi Chimica della proteina wild-type per compararla con quella ricombinante ed 
eventualmente modificazione della proteina per renderla più stabile e/o per migliorare 
le sue proprieta' biofarmaceutiche.  
YFGK LESKLSVIRN LNDQVLFIDQ GNRPLFEDMT DSDCRDNAPR TIFIISMYKD 
SQPRGMAVTI SVKCEKISTL SCENKIISFK EMNPPDNIKD TKSDIIFFQR 
SVPGHDNKMQ FESSSYEGYF LACEKERDLF KLILKKEDEL GDRSIMFTVQ NED  
(I siti di ligazione sono sottolineati in grassetto)  
2) H-IL-32 : Sintesi Chimica della parte N-terminale γ (gamma) isoform (103 residui) 
per compararla con quella ricombinante. 
MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSACDTKD TVGHPGPWRD 
KDPALWCQLC LSSQHQAIER FYDKMQNAES GRGQVMSSLA ELEDDFKEGY LET 
(I siti di ligazione sono sottolineati in grassetto)  
 
Risultati conseguiti. 
1) H-IL-18 
La sequenza della proteina e’ stata divisa in 4 frammenti per poter essere 
sintetizzata utilizzando Native Chemical Ligation. Tutti i frammenti (I, II, III e IV) sono 
stati sintetizzati e purificati. Particolarmente difficili sono state le sintesi dei frammenti 
I e III che sono stati sintetizzati piu’ volte per ottimizzare le rese. 
2) H-IL-32  
Come strategia di sintesi, Il polipeptide e’ stato diviso in quattro frammenti. La sintesi 
piu’ difficile e’ stato il segmento C-terminale che e’ stato risintetizzato 2 volte. Tutti gli 
altri frammenti non hanno avuto alcun problema. Il polipeptide e’ stato effettivamente 
sintetizzato nella sua interezza via Native Chemical Ligation e nei test effettuati dal 
Prof. Dinarello presso L’Universita’ del Colorado a Denver ha mostrato un’attivita’ 
biologica (in presenza di costimuli quali MDP o LPS) comparabile con la proteina 
intera confermando quindi.la validita’ dei dati ottenuti con la proteina ricombinante. 
Infatti il polipeptide in presenza di MDP e’ stato capace, in differenti modelli di indurre 
rispettivamente produzione di IL-6, IL-1β and TNFα. Inoltre sono stati testati anche I 
tre frammenti a maggior numero di residui utilizzati per la sintesi,  
 
 
IL-32: Peptidi testati per attivita’ biologica. 
1) Il-32 gamma isoform 1-103 
2) MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSA (Fragment V) 
3) CDTKD TVGHPGPWRD KDPALW (Fragment VI) 
4) C LSSQHQAIER FYDKMQNAES GRGQVMSSLA ELEDDFKEGY LET 
(Fragment VIII) 
I Frammenti V, VI e VIII  non hanno pero’ evidenziato alcuna attivita’ biologica 
rilevante anche in presenza di costimuli.  
 
3 Summary 
 
Recent advances in the Solid Phase Peptide Synthesis (SPPS) have led to the 
synthesis of polypeptides in a robust and reproducible manner. Nowadays peptide 
fragments up to 60-70 residues can be routinely synthesized with high degree of 
homogeneity. Nevertheless, to chemically synthesize a polypeptide or a small protein 
of 100 residues or more a way to chemically join two peptide fragments is a 
necessity. Several chemoselective ligations have been developed to join unprotected 
peptide fragments in aqueous solution, however most of them do not form a native 
amide bond with a native structure. The most robust and widely used amide forming 
ligation is referred to as Native Chemical Ligation (NCL), which during the last 
decade has extensively demonstrated  its usefulness for the rapid preparation of 
small-medium size proteins with high level of homogeneity. Such methodology 
exploits a chemoselective reaction between two unprotected fragments, a C-terminal 
thioester and a N-terminal cysteine, in aqueous solution at neutral pH thus 
generating a native amide bond at the ligation site.  
In spite of the advances of the recombinant techniques to express, isolate and purify 
the desired protein, the chemical protein synthesis can still overcome some 
unresolved issues related to the use of recombinant material, such as refolding 
following removal of high levels of urea required for extraction from E.coli. In addition, 
the sensitivity of mammalian tissue to endotoxins and other products of microbial 
origin interfere and obscure the biological properties of recombinant cytokines. 
In this study we discuss and tackle the chemical synthesis of two protein 
therapeutics, IL-18 and IL-32, which would greatly benefit from the chemical 
synthesis of their modified analogues. 
 
IL-18 
 
HIL-18 is a proinflammatory cytokine which belongs to the family of IL-1 ligands. 
Initially cloned as an IFN-γ inducing factor, plays a key role in many inflammatory 
diseases including allergy and autoimmune diseases. Recently, after preclinical 
studies on monkeys, therapeutic approaches using recombinant IL-18 have been 
examined for treatment of cancers including a clinical trial in humans indicating the 
necessity for a more stable form that will allow reproducible and reliable therapy for 
clinical uses. Recombinant h-IL-18 has been found to be susceptible of loss of 
biological activity upon storage and handling. Some authors indicated the misfolding 
of the molecule as cause of the loss of biological activity, while others challenged the 
hypothesis of the misfolding indicating the polymerization byproducts as cause of the 
inactivation. A possible explanation is the relative instability of intra-molecular 
disulfide bridges to atmospheric oxidation, which render the molecule prone to inter-
molecular disulfide bond formation.  
Due to the relevance of the medical implications and the potential impact on the 
treatment of some diseases (the molecule is currently under Clinical Trials to treat 
different types of tumors) there is an unmet need to find a more stable form for the 
protein that could lead to a superior drug candidate for the envisaged medical 
applications.   
 
 
 
4 IL-32 
IL-32 is a new inflammatory cytokine. Although IL 32 does not share sequence 
homology with known cytokine families, IL 32 induces various cytokines, human 
TNFα and IL 8 in THP 1 monocytic cells as well as mouse TNFα and MIP 2 in RAW 
macrophage cells.  IL-32 activates typical cytokine signal pathways of nuclear factor 
kappa B and p38 mitogen activated protein kinase. 
Human IL 32 exists as four splice variants and IL 32 from other species were found 
as expressed sequence tag clones in the databank. 
The major problem with IL-32 is first the issue of contamination from E. coli products. 
There is synergism between peptidoglycans from the bacterial wall with IL-32 and 
therefore is not possible to unambiguously evaluate IL-32 alone.  
H-IL-32 γ (gamma) isoform consists of 164 residues. In collaboration with the group 
of Prof. C. Dinarello, we wanted to synthesize the N-terminal segment (103 residues) 
of the γ (gamma) isoform. IL-32 binds to proteinase-1 (PR3) with a high affinity.  
When recombinant IL-32 was exposed to PR3 for 5 minutes, there was an increase 
in biological activity suggesting that the cleavage by PR3 generated a product more 
active.  Prolonged exposure to PR3 resulted in loss of IL-32 activity.  Upon examining 
the potential cleavage sites for PR3 in IL-32, the N-terminal 103 amino acids would 
be generated upon a short exposure to PR3. Other cytokines such as IL-1β and IL-8 
also increase their biological activity following a short incubation with PR3.  
Therefore, the N-terminal 103 amino acid fragment was thought to posses same 
biological activity compared to the whole protein, possibly owning easier handling 
properties due to reduced aggregation. Structurally, it possesses 103 residues with 4 
cysteines and two potentials disulfide bridges.   
 
Objectives: 
 
H-IL-18: Chemical synthesis of the wild-type protein to compare with the recombinant 
version and upon obtained results Chemical protein engineering to stabilize and 
enhance its pharmaceutical properties.  
H-IL-18 consists of 157 residues. 
 
YFGK LESKLSVIRN LNDQVLFIDQ GNRPLFEDMT DSDCRDNAPR TIFIISMYKD 
SQPRGMAVTI SVKCEKISTL SCENKIISFK EMNPPDNIKD TKSDIIFFQR 
SVPGHDNKMQ FESSSYEGYF LACEKERDLF KLILKKEDEL GDRSIMFTVQ NED  
(Bold and underlined are ligation sites) 
 
 
 
 
Results:  
 
All four fragments according to our strategy were finally successfully synthesized and 
purified. At the time being, the ligation steps to assembly the protein are still in 
progress. 
 
H-IL-32: Total chemical synthesis of the N-terminal part of the γ (gamma) isoform 
(103 residues) to compare with the recombinant version. As in the case of IL-18 
since the length of the polypeptide in matter is still significantly above the capabilities 
5 of the SPPS, we had to use a chemical ligation strategy, notably Native 
Chemical Ligation.  
 
MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSACDTKD TVGHPGPWRD 
KDPALWCQLC LSSQHQAIER FYDKMQNAES GRGQVMSSLA ELEDDFKEGY LET 
(Bold and underlined are ligation sites) 
 
Results: 
The full-length N-terminal part 1-103 of the γ (gamma) isoform was synthesized and 
sent along with the intermediate peptide fragments to Prof. Dinarello for biological 
activity tests.  
IL-32: Peptides tested for biological activity 
5) Il-32 gamma isoform 1-103 
6) MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSA (Fragment V) 
7) CDTKD TVGHPGPWRD KDPALW (Fragment VI) 
8) C LSSQHQAIER FYDKMQNAES GRGQVMSSLA ELEDDFKEGY LET 
(Fragment VIII) 
 
Il-32 gamma isoform 1-103 N-terminal amino acids was found to be active in the 
presence of the co-stimulus) MDP.  Previous studies published in Proceedings of the 
National Academy of Sciences demonstrated that MDP synergizes with IL-32 gamma 
for the induction of IL-6.  This synergism was shown to be dependent on caspase-1 
via the induction of IL-1β.  The importance of the observation is that MDP triggers the 
intracellular receptor known as NOD2 (Nuclear Oligomerization Domain).  Patients 
with a forward shift mutation in NOD2 have Crohn’s Disease.  The finding that 
synthetic N-terminal IL-32 103 amino acids synergized with MDP was essential since 
the synthetic 103 peptide lacked any microbial products. Indeed, the polypeptide in 
presence of MDP was able, in different models, to induce respectively production of 
IL-6, IL-1β and TNFα.  
Such results thus confirm and validate the original data obtained with the whole 
protein produced with recombinant techniques. Not unexpectedly, the single 
fragments (Fragment V, VI and VIII) utilized to build the protein as described above 
were each found not to be functional 
 
6 1. Introduction 
 
 
1.1 Relevance of Chemical Protein Synthesis 
 
Protein therapeutics are continuously increasing attention and gaining wider market 
in the pharmaceutical business.1 Recent advances in the bioconjugation techniques 
as well as in the production of biocompatible polymers (i.e. Pegylation) allowed 
enhanced protein therapeutics candidates with improved half-life and reduced side 
effects (immunogenicity) 2. 
Nevertheless, the chemical protein synthesis can still overcome some unresolved 
issues related to the use of recombinant material.3,15 
In this study we will discuss the chemical synthesis of two protein therapeutics, IL-18 
and IL-32, which would benefit from the chemical synthesis of their modified 
analogues. 
 
1.2 Overview of Chemical Protein Synthesis 
Peptide synthesis began in 1901 by Emil Fisher with the synthesis of glycyl-glycine, 
the first synthesis of a free peptide.  
 
 
Fig 1.1 Emil Fisher and his synthesis of glycyl-glycine,1901, from M. Goodman4 
 
After the synthesis of the gly-gly dipeptide many improvements in the technique 
occurred along the years, however until the discovery of the Solid Phase Peptide 
Synthesis (SPPS) 5 by Bruce Merrifield (Nobel Laureate) only small peptides could be 
prepared. Using SPPS, polypeptides of various sizes could be synthesized and upon 
significant advances in the field6 small proteins7 and large polypeptides can be now 
obtained. All methods developed thereafter along the years to bridge the gap from 
peptide to chemical protein synthesis are intrinsically derived from the Merrifield’s 
invention. However, still nowadays synthetic peptides above 60-70 residues cannot 
be routinely prepared in good yield with a high degree of homogeneity. Above such 
limit, poor yields and high impurity often characterize the product made by SPPS. 
 
Incomplete Sequences8  
 
These are formed during the assembly of a sequence :with a 100 amino  
acids synthesis the final yield should be, maximally : 
NH2 CH2 O CH2-CH3
O
NH
NH
O
O
H
+
NH2 CH2 N
H
C
H2
O
OH
O
7 Coupling yield                 final yield
99.99                                99.00
99.90 90.47
99.60                                66.97
99.30                                49.53
99.00                                36.60
98.00 13.26
 
Starting with 250 mg of a resin with a substitution of 0.4 mmoles/g, assuming a 
coupling yield of 99.0 % the theoretical final total yield is 1.1 g, of which 396 mg are 
the correct peptide, and 704 mg are impurities, material in which one or more amino 
acids are missing. These numbers consider only chain assembly, and do not take 
into account side reactions during cleavage and handling.  
RP-HPLC cannot resolve the impurities and separate the pure peptide since the 
change in hydrophobicity due to a single amino acid over 100 a.a. is too small to be 
resolved with current methods.  
Therefore to chemically approach proteins of small and medium size (e.g. 
polypeptide chains greater than 100 a.a. residues) there are two possible solutions:  
1) Developments of new methods for purification of intermediates and final 
products to selectively isolate the desired compound in the complex mixture 
after SPPS.  
2) The necessity to introduce of novel technology to join together 2 or more 
peptide segments with ease and high efficiency. 
 
 
Fig 1.2 Synthesis of peptide fragments: HPLC profile of crude peptides of different 
size of the same molecule9. 
 
1. Development of new purification methods relays on the attachment of a chemical 
probe at the end of the synthesis with a unique chemical moiety. Thus, only the full 
length material functionalized with the unique probe, is finally amenable to further 
react in a chemoselective way with a specific chemical group10. Finally, the 
chemoselective reaction allows the isolation of the full length material. In other cases, 
an hydrophobic and reversible chemical probe (i.e.Fmoc)11 or Tbfmoc12 were added 
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8 at the end of the synthesis, allowing easier purification.  The impossibility to 
remove full length material that underwent to chemical modifications (side reactions, 
incomplete protecting group cleavage) still greatly limits such approach.  
 
2. Possible approaches for fragment condensation: 
A) Fragment condensation with protected peptides  
B) Fragment condensation via enzyme catalysis (peptide ligase) 
C) Chemical Ligation with unprotected peptide fragments 
 
A) Fragment condensation with protected peptides: 
The fragment condensation approach is the oldest strategy to synthesize large 
polypeptides and proteins. Such approach can be further divided in fragment 
condensation with (i) fully protected peptides and (ii) minimal protecting group 
strategy. The first approach with fully protected peptides was pioneered by 
Sakakibara,13 and can count on many successes amongst which the total synthesis 
of GFP14.  Nevertheless, the strategy presents obvious difficulties: purification the 
fully protected peptide fragments, solubilization of protected peptide fragments at 
suitable concentration, and finally possible racemization when the activated residue 
is not a glycine. 
The second approach with partially unprotected peptides is based on a low enthalpic 
activation, which allows hydroxyl moieties to be unprotected thus giving advantages 
in aqueous solubility. This approach was further improved by Ramage15 by using a 
transfer active ester condensation technique and although some interesting 
molecules were synthesized, it has not found many followers. 
 
Fig 1.3 Fragment condensation with protected peptides 
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9  
B) Fragment condensation via enzyme catalysis (peptide ligase): 
The approach was pioneered by Wells16 and co-workers at Genentech. It is based on 
the reversed engineering of enzymes (subtiligase), which under appropriate 
conditions allows peptide bond formation (ligation) rather than cleavage (proteolysis). 
The approach had a significant impact related to the publication on Proceedings of 
the National Academy of Sciences, however along the years the technique did not 
find many followers possibly due to limitation on the sequence alignment suitable for 
the site of ligation.  
C) Chemical Ligation with unprotected peptide fragments: 
Chemical Ligation with unprotected peptide fragments can be further divided into the 
following categories: 
i)  Chemoselective Coupling (Chemical Ligation) of Unprotected Peptides 
      Formation of an « Analog Structure » 
ii)  Native Chemical Ligation 
      Formation of a Native amide Bond with a Native Structure 
 
i)  Chemoselective Coupling of Unprotected Peptides in aqueous medium with 
formation of a non native structure « Analog Structure » 
The chemoselective coupling, can be further divided into two classes: 
Chemoselective  Ligation via Thiol Chemistry and  Chemoselective Ligation via Weak 
Base-Carbonyl Chemistry 
 
 
Fig 1.4  Chemoselective  Ligation via Thiol Chemistry 
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Fig 1.4  Chemoselective  Ligation via weak-base carbonyl chemistry17   
 
The most relevant example of thiol based ligation is the total Synthesis of HIV-1 
Protease via thioester forming chemical ligation by the group of Kent18. In the early 
90s, many groups (especially via recombinant techniques) unsuccessfully tried to 
produce and isolate the HIV-1 protease. The work of Kent’s group allowed the 
isolation of the fully active protein and based upon the information obtained from 
crystallography19 medicinal chemist could design small molecules and peptides that 
are now at the basis of the anti-HIV treatment. 
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Fig 1.5  Chemoselective  Ligation via thioester formation 
 
Concerning Ligation via weak-base carbonyl chemistry, the most efficient and widely 
used is the oxime formation developed by K.Rose20. In another approach, the 
synthesis of a GCSF analogue21 was achieved using hydrazone formation. 
The ligation scheme proposed by Tam22 is of particular interest since generates a 
native amide bond with a non native structure. Amongst the carbonyl based ligations 
is the strategy that best approaches a native architecture by structure similarity: in 
fact replacement of a native proline with hydroxymethyl thioproline as final product of 
the ligation proposed by Tam did not affect biological activity of a HIV-1 protease 
fragment.23 
CHEMOSELECTIVE
REACTION
ANALOG STRUCTURE
NH3
+ COOH
SH
OH
COOH NH3
+
COOH
OH
NH
NH3
+
NH2
OH
NH3
+
COOH
SH
OH
COOH NH3
+
COOH
OH
NH
NH3
+
NH2
OH
COSH Br-CH2-CO
COS-CH2-CO
12
 
 
Fig 1.6  Chemoselective  Ligation carbonyl based via etherocyclic ring formation: 
formation of a native amide bond with a non-native structure 
 
ii) Native Chemical Ligation (NCL): generation of a native amide bond with 
a native structure 
Native Chemical Ligation (NCL)24  has been extensively demonstrated to be the key 
to the rapid preparation of small and medium size proteins with high level of 
homogeneity. In the NCL scheme a C-terminal thioester fragment reacts 
chemoselectively in aqueous solution at neutral pH with an N-terminal cysteine 
peptide. In the first step of the reaction transthioesterification takes place by thiol 
exchange between the free thiol of the N-terminal cysteine and the thioester moiety 
on the other molecule. The newly generated thioester then undergoes an S to N acyl 
shift due to the proximity of the amino group to the thioester functionality, thus 
generating a native amide bond at the ligation site. Native Chemical Ligation (NCL) 
allows the chemical synthesis of proteins from database sequence in a timely and 
cost-effective manner. NCL has become the method of choice for the rapid 
preparation of small and medium cysteine rich proteins.25 
N H 3 + C O O H 
S H 
OH
COOH N H 3 + 
COOH
O H 
N H 
N H 3 + N H 2 
O H 
NH2
SH
C O O H
S H 
OH
CO O H N H 3 + 
N H3 + C O O H 
S H 
OH
COOH N H 3 + COOH
O H 
NH
N H 3 + NH2
O H 
N S
O
OH
O
CHO
O
N H3 + 
COOH
O H 
NH
N H 3 + NH2
O H 
O
O
N
H
S
CAPTURE
REARRANGEMENT 
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 The requirement for cysteine at the site of peptide ligation is an intrinsic 
restriction of the standard NCL strategy. In proteins, cysteine occurs with a 
 
Fig 1.7  Native Chemical  Ligation (NCL) 
 
relatively low frequency; many protein sequences do not have suitably disposed 
cysteines for the NCL strategy and some lack cysteine residues entirely. 
Thus, the continuously increasing demand of large polypeptides and proteins has led 
during the last few years to the development of removable auxiliary groups to extend 
the applicability of NCL to ligation and cyclization of unprotected peptides in aqueous 
solution at an X-X site (where X= any amino acid) 
The first extension of the NCL was presented by Canne et al.26 who exploited two 
acid stable Nα-thiol containing auxiliaries, designed to mimic the side chain of a 
native cysteine. The reductively cleavable Nα-(oxyethanethiol) 1 that has a 1,3-
aminothiol structure, showed a relatively slow amide forming rate while the Nα–(2-
mercaptoethyl) 2, which was not designed to be cleavable, showed superior 
rearrangement rates (Scheme 1). 
 The interesting propensity of the latter to a faster ligation prompted to the design of a 
novel type of auxiliary group that could take advantage of the superior ligation rates 
of 2 and allow its facile and complete removal after ligation. 
  
 
 
 
 
14
 
 
Fig1.8 From SBH Kent27 
 
A case in point is the Nα-(1-phenyl-2-mercaptoethyl) auxiliary28, which combines the 
faster ligation rate of the Nα–(2-mercaptoethyl) group through a 5 membered ring 
intermediate, enabling at the same time its complete removal after ligation. Indeed, 
the 1-phenyl substitution on the Nα–(2-mercaptoethyl) template generates a 
benzylamine derivative that is completely stable in the strong acidic condition used to 
cleave the peptide from the resin (HF, TFA) making the auxiliary compatible with both 
Boc and Fmoc like chemistries. Furthermore, because of the S to N acyl shift intrinsic 
mechanism of NCL, benzylamine to benzylamide conversion occurs during the 
reaction making the auxiliary readily cleavable under similar or milder conditions 
originally required for the cleavage of the peptide.  
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Fig 1.9  Native Chemical Ligation and Extended Chemical Ligation 
 
Furthermore such auxiliary group has been successfully employed for the synthesis 
of cyclic peptides with potential therapeutic interest.29 
However, for all different types of auxiliary groups30 that have been developed to 
extend the application of NCL to other ligation sites, the slower ligation rates 
especially with large fragments and the additional step required to cleave the 
auxiliary post-ligation have reduced their practical utility and use. 
Recently, a novel method to synthesize proteins through a chemical ligation using 
unprotected peptide segments has been presented31. Such scheme does not make 
use of auxiliary groups, instead originally exploits the features of some side chain 
removable functionalities. Ligation rates are high, comparable to NCL and the 
residues available for ligation are more frequent than cysteine. Furthermore the 
whole process is “one pot” and at the end a native polypeptide is obtained directly in 
the ligation mixture. 
The new strategy takes advantage of the benzylic moiety of the aromatic residues to 
release a mercaptan under specific conditions. We use phenylcysteine to exploit 
ligation with thioester fragments and the alkylation post-ligation is designed to 
produce a benzylic thioether suitable for cleavage. Benzyl groups are commonly 
employed in peptide synthesis to protect side chain functionalities via ether (Ser and 
Thr) and thioether (Cys) bonds. Thus, after ligation, alkylation of the free mercaptan 
generates a benzyl thioether suitable for cleavage. 
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Fig 1.10 Native Chemical Ligation at Aromatic Residues (Phe, Tyr and Trp). 
 
 
 
 
 
 
1.3 Problems related to the clinical use of therapeutic cytokines 
 
 
Although cytokine biology has advanced rapidly with the ability to produce 
recombinant molecules in E.coli, the field still suffers from problems related to low 
biological activities and the problems of endotoxin contamination as well as 
peptidoglycan. This latter issue is of paramount importance in testing new cytokines 
such as interleukin-IL-32. However, it is particularly a problem for some cytokines 
such as IL-1b and IL-18. In the case of IL-1b, the natural molecule is produced as an 
inactive precursor and the intracellular enzyme caspase-1 cleaves the precursor into 
an active cytokine. However, the N-terminal peptide in E. coli exhibits variable 
biological activities (variable specific activities in terms of units/milligram).   The 
variability appears to be due to more than one reason. For example, deletion of the 
terminal methionine from the E- coli product enhances specific activity and arginine in 
position number 4 appears to be critical.  Most of the problems with human 
recombinant IL-1b are now resolved but it remains an excellent example of the 
problem of assessing biological activities of new molecules. Naturally, endotoxin 
content always remains a significant confounding issue. In the case of IL-1b, the 
ability to study its pyrogenic properties requires strict removal of endotoxins. IL-18 is 
a recent example. Recombinant mouse IL-18 produced in E.coli is biologically active 
in the picomolar range, similar to several proinflammatory cytokines. However, 
human IL-18 remains problematic in that one needs nanomolar concentrations. 
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 IL-18 and IL-32 
 
 
 
 
1.4. IL-18 
 
H-IL-1832 is a cytoplasmic protein produced as biologically inactive 24 kDa precursor 
that requires to be cleaved by caspase-1  into the biologically active mature 18 kDa 
molecule. IL-18 is a proinflammatory cytokine which belongs to the family of IL-1 
ligands, initially cloned as an IFN-γ inducing factor, plays a key role in many 
inflammatory diseases including allergy and autoimmune diseases33. Notably, IL-18 
by inducing production of IFN-γ from T cells, has been successfully used to boost 
immune-defense in mice to treat tumors34. Recently, after preclinical studies on 
monkeys35, therapeutic approaches using recombinant IL-18 have been examined for 
treatment of cancers including a clinical trial in humans indicating the need for a more 
stable form that will allow reproducible and reliable therapy for clinical uses. 
 
 
Fig 1.11 Functions of IL-18 
 
Recombinant h-IL-18 has been found to be susceptible of loss of biological activity 
upon storage and handling. IL 18 induces Interferon gamma but depending on the 
folding of the molecule and the state of disulfide bonds (S-S) reduction, the induction 
of IFNγ (gamma) can be different by a factor of 10 or more. Naturally this is a 
problem in human trials. Depending on the specific activity (induction of IFNγ units/ 
milligram of IL-18), this can vary if the protein is not stable or folded correctly. These 
issues of low activities of IL-18 were discussed by the group of C. Dinarello.36 Some 
authors37 indicated the misfolding of the molecule as cause of the loss of biological 
activity.  
Recently though, another paper38 challenged the hypothesis of misfolding indicating 
the polymerization byproducts as cause of the inactivation. A possible explanation is 
h-IL-18 
Inflammation Stimulation of Immuno System 
( Anti-tumor activity)  (Pro-Inflammatory activity) 
IFN
T cells 
GM-CSF 
Chemokine
Functions of human IL-18 
NK cells 
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 the relative instability of intra-molecular disulfide bridges to atmospheric 
oxidation, which render the molecule prone to inter-molecular disulfide bond 
formation.  
Due to the relevance of the medical implications and the potential impact on the 
treatment of some diseases (the molecule is currently under Clinical Trials to treat 
different types of tumors) there is an unmet necessity to find a more stable form for 
the protein that could lead to a superior drug candidate for the envisaged medical 
applications.  
 
1.5 IL-32 
 
IL-32 is a new inflammatory cytokine.  
14 years ago a cytokine like molecule described as natural killer cell transcript 4 
(NK4)39 was discovered, but its function remained unknown until recently. 
Increased gene expression of NK4 has been reported in PBMC from patients 
receiving high dose IL 2 therapy for malignant melanoma40, but the function of NK4 
has remained unknown until the recent study by the group of Dinarello41. 
NK4 was then found to be a novel inflammatory cytokine and re-named asIL-32, and 
its biological function, regulation of production, genomic structure and signal 
transduction has been described33. Although IL 32 does not share sequence 
homology with known cytokine families, IL 32 induces various cytokines, human 
TNFα and IL 8 in THP 1 monocytic cells as well as mouse TNFα and MIP 2 in RAW 
macrophage cells.  IL-32 activates typical cytokine signal pathways of nuclear factor 
kappa B and p38 mitogen activated protein kinase. 
Human IL 32 exists as four splice variants and IL 32 from other species were found 
as expressed sequence tag clones in the databank. 
 
Fig 1.12  The genomic organization of four IL-32 splice variants and other species of 
IL-32 by amino acid sequence alignment, from Soo-Hyun Kim et others39. 
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The major problem with IL-32 is first the issue of contamination from E. coli products. 
There is synergism between peptidoglycans from the bacterial wall with IL-32 and 
therefore, so is not possible to evaluate IL-32 alone.  
The next problem is aggregation of the gamma isoform:  
The alpha isoform is produced in high amounts from E. coli but the activity is 
extremely low compared to the gamma isoform.   
Finally the gamma isoform production is also low. 42 
h-IL-32 γ (gamma) isoform consists of 164 residues. In collaboration with the group 
of Prof. C. Dinarello, we wanted to synthesize the N-terminal fragment (103 residues) 
of the γ (gamma) isoform50. The N-terminal fragment was thought to posses same 
biological activity compared to the whole protein, possibly owning easier handling 
properties due to reduced aggregation33. Structurally, it possesses 103 residues with 
4 cysteines and two potentials disulfide bridges.  
There is also a need for IL-32 reagents for making neutralizing antibodies. First, the 
synthetic peptides and antibodies to these may help in the development of better 
ELISA detection methods. Indeed, having synthetic active peptides for IL-32 (such as 
103 IL 32 γ and even smaller peptides), biologists can make monoclonal antibodies 
and look for epitopes for neutralization. These may then become therapeutic agent in 
treating Myelodysplastic Syndrome43, COPD44, rheumatoid arthritis45, M. 
tuberculosis46 and Crohn’s Disease55 .  
There is also a therapeutic role for IL 32 in HIV-147  
 
2. Aim of the thesis 
 
Objectives: 
1) H-IL-18 
Chemical synthesis of the wild-type protein to compare with the recombinant 
version and upon obtained results Chemical protein engineering to stabilize and 
enhance its pharmaceutical properties.  
H-IL-18 consists of 157 residues. 48 
Sequence of h-IL-18 
 
YFGK LESKLSVIRN LNDQVLFIDQ GNRPLFEDMT DSDCRDNAPR TIFIISMYKD 
SQPRGMAVTI SVKCEKISTL SCENKIISFK EMNPPDNIKD TKSDIIFFQR 
SVPGHDNKMQ FESSSYEGYF LACEKERDLF KLILKKEDEL GDRSIMFTVQ NED  
(Bold and underlined are ligation sites) 
 
Fragment I: 
YFGK LESKLSVIRN LNDQVLFIDQ GNRPLFEDMT DSDCRDNAPR TIFIISMYKD 
SQPRGMAVTI SVK- CαSR  
 
Fragment II: 
C(thiaz)EKISTL SCENKIISFK E(Fm)49 - CαSR 
 
Fragment III: 
hCys50(thiaz)NPPDNIKD TKSDIIFFQR SVPGHDNKMQ FESSSYEGYF LA- CαSR  
Fragment IV  
CEKERDLF KLILKKEDEL GDRSIMFTVQ NED  
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 2) H-IL-32 :  
Total chemical synthesis of the N-terminal part of the γ (gamma) isoform (103 
residues) to compare with the recombinat version. Again, as in the case of IL-18 
since with the length of the polypeptide in matter is significantly above the capabilities 
of the SPPS, we had to use a chemical ligation strategy.  
MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSACDTKD TVGHPGPWRD 
KDPALWCQLC LSSQHQAIER FYDKMQNAES GRGQVMSSLA ELEDDFKEGY LET 
(Bold and underlined are ligation sites) 
 
MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSA- CαSR (Fragment V) 
C(thiaz)DTKD TVGHPGPWRD KDPALW CαSR (Fragment VI) 
C(thiaz)QL- CαSR (Fragment VII) 
C LSSQHQAIER FYDKMQNAES GRGQVMSSLA ELEDDFKEGY LET (Fragment 
VIII) 
 
N-terminal fragment:1-35 Cα-COS-R 
Intermediate fragment: 36-56: nterminal cys(thiazolidine) Cα-COS-R 
C-terminal fragment 57-103: Ligation 57-59 with 60-103 to overcome synthetic and 
solubility issue of the fragment 
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 3. Results and discussion 
 
Peptides were synthesized using Boc chemistry In Situ neutralization chemistry as 
pioneered by Steve Kent5. Cα-thioester peptides were prepared according to the 
protocol of Hackeng et al.51. Chemical ligation of peptide fragment was carried out 
from C termini to N termini direction, N terminal 1-2 amino thiol (i.e. cysteine) was 
protected through thiazolidine formation.52. Chemical ligations were carried out as 
described in the material and methods section. 
 
3.1 IL-18 
Results Obtained 
 
Originally, the synthesis was designed in 3 fragments ligation: 1-67, 68-126 and the 
C-terminal fragment 127-157. Particularly difficult was the synthesis of the N terminal 
fragment both for the size and solubility problems. The N-terminal fragment 1-67-C-
terminal thioester gave initially solubility problems leading to poor yields after 
purification. Finally the 1-67 was successfully synthesized adding 3 lysines residues 
on the thioester part to overcome solubility problems due to its polycationic feature as 
described in Fig 3.1. 
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Fig. 3.1 Thioester comparison 
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 IL18 Synthetic Strategy 
 
Due to its high number of residues, the N terminal fragment was synthesized from 
residue 1 untill threonine 34 utilizing standard In Situ neutralization5 chemistry at 0.2 
mmol scale resin substitution; Then 50 % of the resin was removed, thus the 
synthesis was finally carried out and completed at 0.1 mmol scale with capping at the 
end of each cycle using acetilglycine. 
 The C terminal portion 127-157 was prepared in straightforward way without any 
special modification, however the middle fragment 68-126 was impossible to be 
synthesized even upon several unsuccessful attempts. Thus we changed strategy 
and in order to shorter the size of the fragment we decided to use the homocysteine 
ligation41 developed by the group of Tam, who exploited thioester ligation with a N-
terminal homocysteine residue resulting in a native methionine residue generation 
upon post  ligation S-methylation. Thus the original middle fragment (68-126) was 
further divided in two segments, 68(CysThiaz)-85Glu(OFM)-thioester and 
hcys(Thiaz)86-126-thioester. The Glutamic residue position 85 Cα thioester needed to 
be protected during ligation to avoid formation of undesired gamma glutamic peptide 
backbone40. The homocysteine with 1,3 amino thiol masked through heterocyclic ring 
(like thiazolidine for the cysteine) is not commercially available. Thus, the protection 
of the 1,3 aminothiol through heterocyclic ring formation occurred after HF cleavage 
in TFA buffer as described by Villain et al.53  
 
 
 
Fig.3.2 IL-18 Thiazolidine formation 
 
All four fragments according to our new strategy were finally successfully synthesized 
and purified. At the time being, the ligation steps to assembly the protein are still in 
progress. N-terminal protected fragment III was then ligated with fragment IV forming 
fragment III+IV. Trial ligation occurred almost quantitavely by HPLC measurement, 
however a des-Asn (Asparagine deletion), impurity carried over from chain assembly 
of fragment III is still present after ligation (Fig 3.13).  
 
Characterization of IL-18 Fragments 
 
Fragment I, IL 18 N-terminal 1-67-CαSR, expected M+H 8157.4, found ES MS 8157, 
Maldi MS 8160.5 
Fragment II, IL 18 Cys(Thiaz)68-85-E(OFm)- CαSR, expected M+H 2448, found ES 
MS 2449, Maldi MS 2450 
Fragment III, IL 18 hcys(PG)86-126-CαSR, expected M+H 5118, found ES MS 5119 
Fragment IV, IL 18 C terminal127-157, expected M+H 3743, found ES MS 3743, 
Maldi MS 3742 
SH 
2HN 
C O
SR Acetaldeide
fragment III 
S
HN
C O
SR
N-terminal closed fragment III 
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Fig.3.3 IL-18 C Terminal Frangment (IV): MS analysis of purified fragment 
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Fig.3.4 IL-18 C Terminal fragment: HPLC analysis 
 
Fig.3.5 HPLC analysis of IL-18 Fragment III 
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Fig.3.6 IL-18 Fragment III MS Analysis. Note impurity present due to uncompleted coupling 
of asparagine (Asn). 
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Fig.3.7 IL-18 Fragment II: HPLC analysis 
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Fig.3.8 IL-18 Fragment II:Maldi MS analysis 
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Fig.3.9 IL-18 Fragment II: MS analysis 
IL18_fram m ento 2 #18 RT: 2.00 NL: 2.57E7
F: + c ESI Full m s  [ 400.00-2000.00]
1600 1800 2000 2200 2400 2600 2800 3000 3200 3400
m ass
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
Ab
un
da
nc
e
2449.9
2437.9
3266.61633.3
2471.0
2494.6 3250.91625.5
2731.32536.62336.6 2945.81963.9 3116.6 3279.5 3498.71661.8 2775.32077.71749.3 2205.91615.5
IL18_fram mento 2 #319-336 RT: 13.16-13.69 AV: 18 NL: 2.22E7
F: + c ESI Full ms  [ 400.00-2000.00]
500 1000 1500 2000 2500 3000 3500
m /z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
+1
2450.8
+2
1225.9
+3
817.7
+4
613.5
28
 
 
Fig.3.10 IL-18 N Terminal (Fragment I) 1-67. Maldi MS analysis 
 
Fig.3.11IL-18 N Terminal (Fragment I) 1-67. HPLC analyis,  
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Fig.3.12 IL-18 N Terminal (Fragment I) 1-67. MS analysis 
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 Ligation III+IV [86-126] + [127-157] MW: 8492 amu 
 
 
 
Fig.3.13 IL-18 Ms Product Ligation Fragment III and IV  
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 Ligation Strategy to assembly IL-18 
 
Ligation product from fragments III and IV will be first protected at the cys 127 
(ligation site) with Acm group under strong acidic conditions as described by the work 
of Albericio54. Similarly, Fragment II was protected at the cys 76 with Acm (Fig. 3.13 
below). Then after selective deprotection of the 1,3 amino thiol of the N terminal hcys 
86-157, the N-terminal free hcys fragment can undergo to ligation with Cα-thioester 
Fragment II cys(Acm) 76 protected. 
 
 
 
Fig.3.14 IL-18 Fragment II Acm protection  
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Under this strategy, the ligation product of segments II +III + IV will own a linear 
polypeptide with only one free thiol moiety, which upon methylation results in a native 
fragment with methionine 86 at the ligation site. Finally, upon deprotection of the 1,2 
amino thiol of the cys 68, the N-terminal free cys polypeptide 68-157 is amenable to 
react with the thioester fragment I (1-67) to yield, after cys Acm deprotection, the 
linear full length native chemically assembled IL-18 1-157. 
 
 
 
 
 
Cartoons describing the IL-18 synthesis development 
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 3.2  IL-32 
 
At certain point during the development of our study the chemical synthesis of h-IL-
32 became a priority due to its relevance in inflammatory and autoimmune diseases.  
Although several of immune regulatory molecules have been discovered during the 
past decade, many phenomena remain unexplained in understanding immune 
regulation. The functional portfolio of the cytokine IL 32 can now help unravel the 
complexity of cytokine biology. In spite of many advances in the recombinant protein 
expression, the difficulties encountered in the expression of the protein variants 
concerning both the quantity and purity of the obtained material (absence of toxins 
and other biological contamination such as for example peptido-glycans) rendered 
the chemical synthesis of the polypeptide truly necessary in order to unambiguously 
confirm the scientific data so far obtained by C. Dinarello and co-workers. Paolo, you 
can insert the references here). Indeed, should the polypeptide chemically 
synthesized (and thus devoid of toxins and other biological contamination) confirming 
the previous results obtained with the recombinant material, that would finally prove 
the existence of new inflammatory and immune pathways. We began our work by 
synthesizing the N-terminal γ (gamma) isoform consisting of 103 residues. Indeed, 
studies from C.Dinarello and co-workers indicated it as the shortest polypeptide that 
should own biological activity comparable to the entire functional protein. This was 
based on the cleavage site of PR355. Assuming the polypeptide in matter could then 
show the desired or at least significant biological activity, in a second phase of the 
project the synthesis of the whole protein could be tackled.  However, having a 
synthetic peptide without any contamination will be of great value in finding a specific 
receptor.  The receptor can be a surface receptor on an intracellular receptor. 
Our initial strategy was to synthesize the polypeptide by Native Chemical Ligation 
assembly of only three peptide segments. However the middle fragment, when 
synthesized the first time, showed unexpected solubility problems. Thus it was further 
divided in two segments: a short fragment of 3 residues (Fragment VII) 57-59 and 
fragment VI, 36-56 thus making a total of four fragments. The C terminal fragment 
VIII, 60-103 was synthesized two times. The other 3 fragments were synthesized 
without any changes from standard Boc chemistry with In situ neutralization. Each 
fragment was purified by HPLC semi-preparative and each ligation reaction was first 
tried on analytical scale (0.5-1.0 mg scale) and then ligation was scaled up to multi-
mgs scale. Finally the ligation mixture was purified by semi-preparative HPLC.  
The full-length N-terminal part 1-103 of the γ (gamma) isoform was synthesized and 
sent with the intermediate fragments to Prof. Dinarello for biological activity tests. 
 
Characterization of IL-32 Fragments and ligation product 
 
MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSACDTKD TVGHPGPWRD 
KDPALWCQLC LSSQHQAIER FYDKMQNAES GRGQVMSSLA ELEDDFKEGY LET  
Theoretical pI/Mw: 5.26 / 11570.25 
 
IL-32 C-terminal 60-103 Fragment VIII =Expected 5042.5, found 5043 
IL-32 57-59 thioester, Fragment VII MWth=561  
IL-32 36-56 thioester, Fragment VI MWth= 2760 
IL-32 1-35 thioester, Fragment V MWth= 4011  
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 Ligation Products : 
 
IL 32 57-103 (Ligation fragments VII +VIII) expected, found 5398; (expected after 
thiazolidine ring opening 5386., found 5385);  
IL 32 36-103 (Ligation fragments VI + C-terminal 57-103), , expected 7775, found 
7775; (7763.5 expected after thiazolidine ring opening, found 7763.8);   
IL-32 1-103, Ligation fragment V with 36-103, IL-32 gamma 1-103, expected, 
11570.2, found, 11570; After folding, expected 11566, found: 11568 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.15 IL-32 Fragment VIII, HPLC analysis. 
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Fig.3.16 IL-32 Fragment VIII, MS analysis. 
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Fig.3.17 IL-32 Fragment VII, HPLC and MS analyses. 
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Fig.3.18 IL-32 Fragment VI, HPLC of Crude 
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Fig.3.19 IL-32 N-Terminal Fragment V: HPLC and MS:  
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 IL-32 Ligation Strategy 
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Fig.3-20. IL-32 Synthetic Strategy 
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 IL-32 synthesis through ligation reactions 
 
Ligation IL-32 57-59+60-103, MWth=5398 amu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.21 IL-32 Ligation Fragments VII and VIII 
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Fig. 3.22. Ligation Middle Fragment VI+C-term Fragment 57-103 
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Fig.3.23 MS IL-32 Ligation Fragments VII and C-term Fragment 57-103  
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 Ligation to form IL-32 36-103. Il-32 C terminal 57-103, 10mg was reacted Il 32 
Fragment VI (middle segment) 5.7 mg, at pH 7.00 in presence of thiophenol as 
catalyst. Ligation product was purified on HPLC semi-preparative on a C4 column 
using a gradient 10% b to 60% B in 60 minutes. After purification we recovered 9.36 
mg, corresponding to a yield of 65%. 
The ligation product was then treated with O-methyl hydroxylamine (0.5M) in acid 
condition to open thiazolidine ring to free the n-terminal 1,2 amino thiol.  
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Fig.3.24 IL-32 ligation product 36-103 after thiazolide ring opening : A) HPLC, B) Ms 
raw charged state product, C) deconvoluted MS product 
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 semi-preparative on a C4 column. Recovered 1.4 mg after purification, with yield 
of 20% 
 
 
 
Fig.3.25 IL-32 HPLC Ligation Fragments V and 36-103 
 
 
Fig.3.26 IL-32 Gel of linear full length IL- 32 1-103  
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Fig.3.27 IL-32 MS of linear IL- 32 1-103  
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Fig.3.28 IL-32 HPLC of linear IL- 32 1-103  
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Fig.3.29 IL-32 MS refolding IL- 32 1-103  
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 3.3 IL-32: Peptides tested for biological activity 
 
Il-32 peptides tested: 
9) Il-32 gamma isoform 1-103 
10) MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSA (Fragment V) 
11) CDTKD TVGHPGPWRD KDPALW (Fragment VI) 
12) C LSSQHQAIER FYDKMQNAES GRGQVMSSLA ELEDDFKEGY LET 
(Fragment VIII) 
 
Results of Biological Test 
 
1) Il-32 gamma isoform 1-103 was found to be active in presence of the costimulus 
MDP. Indeed, the polypeptide in presence of MDP was able, in different models, to 
induce respectively production of IL-6, IL-1β and TNFα56.  The synthetic IL-32γ 1-103 
was also active in combination with LPS.  In addition, IL-32 1-103 was active in 
differentiation of human monocytes into macrophages, see Netea (Proceedings of 
the National Academy of Sciences).57 
Such results thus confirm and validate the original data obtained with the whole 
protein produced with recombinant techniques.   
Unfortunately the single fragments (Fragment V, VI and VIII) utilized to build the 
protein as described above were all found not to be functional. 
 
Synthetic N-terminal IL-32g induced cytokines  
in human PBMC, courtesy of Prof.C. Dinarello 
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 4. Conclusions 
 
During the last decade, many advances both on peptide synthesis and ligation 
chemistry rendered accessible the total chemical synthesis and engineering of 
medium size proteins up to 180 residues.  
We successfully synthesized all peptide fragments of Il-18 suitable for protein 
synthesis using Native Chemical Ligation and we successfully assembled and tested 
the Il-32 γ (gamma) isoform. 
While the assembly of the IL-18 protein is still in progress, the biological tests of IL-32 
1-103 gamma isoform we synthesized confirmed and validated the original data 
obtained with the whole protein produced with recombinant techniques and the 
synthetic material will be soon tested in many in vivo models by the group of Prof. C. 
Dinarello. The chemically synthesized IL-32 γ 1-103 N-terminal amino acids was 
found to be active in the presence of the co-stimulus MDP.  Previous studies 
published in Proceedings of the National Academy of Sciences demonstrated that 
MDP synergizes with IL-32 gamma for the induction of IL-6.  This synergism was 
shown to be dependent on caspase-1 via the induction of IL-1β.  The importance of 
the observation is that MDP triggers the intracellular receptor known as NOD2 
(Nuclear Oligomerization Domain).  Patients with a forward shift mutation in NOD2 
have Crohn’s Disease.  The finding that synthetic N-terminal IL-32 103 amino acids 
synergized with MDP was essential since the synthetic 103 peptide lacked any 
microbial products. Indeed, the polypeptide in presence of MDP was able, in different 
models, to induce respectively production of IL-6, IL-1β and TNFα.  
There is also a need for IL-32 reagents for making neutralizing antibodies.  The 
synthetic peptides and antibodies to these may help in the development of better 
ELISA detection methods. Furthermore the synthetic material will be useful to make 
monoclonal antibodies and look for epitopes for neutralization to cure 
Myelodysplastic Syndrome, COPD, rheumatoid arthritis, M. tuberculosis and Crohn’s 
Disease. 
Chemically synthesized IL-18 will unambiguously elucidate the mechanism of its 
inactivation testing the theory about disulfide bridging and its enhanced version may 
constitute an effective therapeutic agent for some form of cancer. 
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 5. Experimental Section 
Materials 
 
Amino acids used for Boc chemistry peptide synthesis were, Tyr(2BrZ), Asp(OChx), 
Thr(Bzl), Ser(Bzl). Boc amino acids were obtained from Peptides International, USA. 
HBTU was from Luxembourg Science. DCM, DMF, TFA were purchased from Fluka. 
Pam resin was purchased from Novabiochem. 
Protected Na-Fmoc-amino acid derivatives, coupling reagents and Rink amide MBHA 
resin were purchased from Calbiochem-Novabiochem 
(Laufelfingen, Switzerland). S-trityl-mercaptopropionic acid was obtained from 
Peptides International (Louisville, Kentucky 40224 USA), DIEA was from Applied 
Biosystem (Foster City, CA). All other chemicals were commercially available by 
Sigma-Aldrich or Fluka (Bucks, Switzerland) or LabScan (Stillorgan, Dublin, Ireland) 
and were used as received unless otherwise stated. D2O was purchased by Sigma 
Aldrich (99.96% D). 
 
 
Solid Phase Synthesis 
 
All peptides were prepared by SPPS using machine-assisted protocols on a custom-
modified Applied Biosystems model 430A and 4333A peptide synthesizers. Peptides 
were synthesized on the appropriate Boc-aminoacyl-OCH2-Pam preloaded resin. 
Thioester resins are prepared according to the procedure of Hackeng et al. starting 
from the MPAG resin (b-mercapto-propionic acid-Glycine) following a published 
procedure using PyBop as activator. SPPS was performed using in situ neutralization 
with the HBTU activation procedure for Boc chemistry as described by Kent.  
Bromoacetic acid was coupled manually to the N-terminal free amine peptide resin 
after standard neutralization cycles. After chain assembly was completed, the desired 
peptide was simultaneously deprotected and removed from the resin by treatment 
with anhydrous HF containing 5% p-cresol, and lyophilized. Peptides were 
characterized by analytical RP-HPLC Waters 2690 HPLC module with 214 nm UV 
detection, using a Symmetry 300 C8 column (5 mm, 0.46x 15 cm) with a linear 
gradient of buffer B in buffer A typically over 30 minutes at 1.0 mL/mi or by on a 
Shimadzu 10A-LC using a Phenomenex.C18 column (Torrance, CA), 4.6 x 250 mm 5 
mm, eluted with an H2O/0.1%TFA (A) and CH3CN/0.1% TFA (B). 
Peptide fragments were purified by preparative RP-HPLC on a Waters 600 HPLC 
module, using a C18 Waters DeltaPak preparative column (5 ´ 25 cm; 10 mm). at 12 
mL/min.  
Peptide identity was confirmed by MALDI/TOF STR DE (PE Biosystems, Foster City, 
CA) and ESI-MS that was performed with a Bruker Esquire 3000 Ion Trap (Bruker 
Daltonics, Bremen, DE). 
.  
Ligation reaction 
The C-terminal unprotected peptide (1.5 equivalent) and the N–terminal peptide (1 
equivalent) were solubilized in freshly degassed 6M guanidinium hydrohloride, 0.2 M 
sodium phosphate, pH 7.5 buffer at a concentration of 2.5 mM each. After addiction 
of 1% thiophenol the pH was adjusted to 7.0. Aliquots of this solution were treated 
with equal volumes of BME for 5 minutes and then of 10% TCEP for 10 minutes to 
completely hydrolyse any thiol abduct before HPLC analysis. Ligation reactions 
54
 analysis was conducted using a gradient starting from either 10 % of B with a 
gradient slope of 1.66 % of B for minute. Base line resolution of the different 
isomerization product was achieved using a gradient starting at 20 % of B and with 
an increase of 0.33 % B for minutes. Peptide identity was confirmed by using MALDI-
MS and/or HPLC and ESI-MS until reaction completion. 
Conversion of Thz-to Cys-peptide was performed by 20% BME for 30 minutes, 
adding then 3% acetic acid and 0,5 M methoxy-amine×HCl, causing the pH of the 
reaction mixture to drop to »4. The reaction was vortexed for 3 hours. Then, this 
solution was treated with 10% TCEP for 10 minutes to completely hydrolyse any thiol 
adduct before HPLC analysis. The reaction was monitored by using MALDI-MS 
and/or HPLC and electro-spray ionization-MS until completion. 
 
Post cleavage S-Acm peptide protection  
 
The IL-18 Fragment II, 2.5 mg, ~ 1 micromol, was dissolved in 400 uL of water, then 
800 uL of 1:3 TFMSA:TFA were added. The solution was stirred while an argon 
atmosphere was created. 30 eq. of Acm-OH dissolved in 100 uL of 1:3 TFMSA:TFA 
were added and the mixture was left under stirring over night. The solution was 
monitored by HPLC before and after reaction. A MALDI-MS spectrum was also 
recorded on a solution aliquot to assess the MW increase (expected ΔM = 72 amu). 
Results: 
Upon HPLC analysis, the main peak of the N-terminus protected thioester, shifted 
about 10 minutes while still retaining an Fmoc spectrum due to the C-terminal Fm-
protected Glutamic acid. Importantly, MALDI-MS analysis showed the expected 
increase of 72 amu, confirming the incorporation of the Acm group. 
C(Thiaz)EKISTLSC(Acm)ENKIISFKE(Fmoc)-Thioester Expected  2521, found 2521 
 
HPLC 
Analytical RP-HPLC (reverse-phase high performance liquid chromatography) was 
performed using a column 250 × 4 mm i.d. packed with Nucleosil 300-A, 5μm C8 
particles. The flow rate was 0.7 mL/min, and effluent was monitored at 214 nm. 
Peptides were purified on a C8 semi-preparative column (250 × 10 mm i.d. Nucleosil 
300-A, 5 μm particle size) at a flow rate of 4 mL/min monitored at 214 nm, or purified 
on a Vydac C8 preparative column (250 × 22 mm i.d., 10 μm particle size) at 15 
mL/min monitored at 214nm. Solvents used in RP-HPLC were as follows: A, 0.1% 
TFA (1 g TFA in 1 L H2O); B, 0.1% TFA in 90% acetonitrile (1 g of TFA mixed with 
100 mL of H2O and then brought to 1 L with acetonitrile). Generally, the conditions 
used in analytical work were 2 min isocratic at 20% B followed by a linear gradient to 
65% B over 45 min. In preparative work a linear gradient (usually of the same slope) 
was used after 2min at initial conditions. All peptide components were collected 
manually at the detector exit, evaporated at room temperature under reduced 
pressure, frozen, and then recovered by lyophilization. 
 
Mass spectrometry 
Electrospray ionization mass spectrometry (ESI-MS) was performed in positive ion 
mode on a Platform-II instrument (Micromass, Manchester, England). Samples were 
introduced at 10 μL/min in solvent acetonitrile/water/formic acid (49.9:49.9:0.2). 
MALDI-TOF mass spectrometry was performed in linear mode using sinapinic acid 
as matrix on a Voyager Elite machine (Applied Biosystems Foster City, CA) equipped 
with delayed extraction. External calibration was performed on the electrospray 
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 machines using a solution of horse heart apomyoglobin and on the MALDI-TOF 
machine using the mixture of peptides supplied by the manufacturer. 
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Abbreviations 
 
The utilized abbreviations for natural amino acids and for peptides are in agreement 
with the IUPAC-IUB Commission on Biochemical Nomenclature (IUPAC-IUB, 1984; 
1989). 
 
? ACN : Acetonitrile 
? BME : 2 mercapto-ethanol 
? t-Boc tert-butyloxycarbonyl 
? t-Bu: ter-butyl 
? CD: Circular Dichroism 
? COSY: COrrelation SpectroscopY 
? 1D, 2D, 3D: mono-, bi-, three-dimensional 
? DCM: Dichloromethane 
? DIEA: Diisopropylethylamine 
? DMF: Dimethylformamide 
? DMSO: Dimethyl sulfoxide 
? DMAP: Dimethylamino-pyridine 
? Dnp: 2,4-dinitrophenyl 
? DTT: 1,4-dithiothreitol 
? ESI: ElectroSpray Ionization 
? Fmoc: 9-fluorenylmethyloxycarbonyl 
? HATU:O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
? HBTU: 2-(1H-Benzotriazole-1-yl)-1,1,3,3,tetramethyluronium 
hexafluorophosphate 
? HF: hydrogen fluoride 
? HOBt: 1-hydroxybenzotriazole 
? MALDI-TOF: Matrix Assisted Laser Desorption Ionization -Time of Flight 
? NMR: Nuclear Magnetic Resonance 
? NMM: N-methylmorpholine;  
? NCL: native chemical ligation 
? NOE: Nuclear Overhauser Enhancement 
? NOESY: Nuclear Overhauser Enhancement and exchange SpectroscopY 
2 ? OdiMeOPac: (2´´-4´´-dimethoxy)-phenacyl group;  
? OFm: 9-fluorenylmethyl ester;   
? OMop: 1-methyl-2-oxo-2-phenylethyl ester;  
? OPac:  phenacyl esters;  
? OPse: phenylsulfonyl)ethyl ester;  
? OTce: 2,2,2-trichloroethyl esters;  
? Pam: 4-hydroxymethylphenylacetic acid; 
? PyBop: benzotriazolyl N-oxytrispyrrolidinophosphonium 
hexafluorofluorophosphate 
? Rink Amide MBHA Resin: 4−2’, 4’- Dimethoxyphenyl – Fmoc - aminomethyl)-
phenoxyacetamidonorleucyl-MBHA resin 
? RP-HPLC: Reverse Phase-High Performance Liquid Cromatography 
? SPPS: Solid Phase Peptide Synthesis 
? TFA: Trifluoroacetic acid 
? Thz: Thiazolidine 
? TMS: trimethylsilane 
? TOCSY: TOtal Correlation SpectroscopY 
? Tris: Tris(hydroxymethyl)aminomethane 
? Trt: trityl 
? UV-vis: Ultra Violet- Visible
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New HIV prevention methods are needed, and among those currently being explored are “microbicides”, substances
applied topically to prevent HIV acquisition during sexual intercourse. The chemokine analogue PSC-RANTES
(NR(n-nonanoyl)-des-Ser1-[L-thioprolyl2, L-cyclohexylglycyl3]-RANTES(4–68)) is a highly potent HIV entry
inhibitor which has shown promising efficacy in its initial evaluation as a candidate microbicide. However, a way
must be found to produce the molecule by cheaper means than total chemical synthesis. Since the only noncoded
structures are located at the N-terminus, a possible solution would be to produce a protein fragment representing
all but the N-terminal region using low-cost recombinant production methods and then to attach, site specifically,
a short synthetic fragment containing the noncoded N-terminal structures. Here, we describe the evaluation of a
range of different conjugation chemistries in order to identify those with potential for development as economical
routes to production of a PSC-RANTES analogue with antiviral activity as close as possible to that of the parent
protein. The strategies tested involved linkage through oxime, hydrazone/hydrazide, and Ψ[CH2-NH] bonds, as
well as through a peptide bond obtained either by a thiazolidine rearrangement or by direct R-amino acylation of
a protein fragment in which 4 of the 5 lysine residues of the native sequence were replaced by arginine (the fifth
lysine is essential for activity). Where conjugation involved replacement of one or more residues with a linker
moiety, the point in the main chain at which the linker was introduced was varied. The resulting panel of 22
PSC-RANTES analogues was evaluated for anti-HIV activity in an entry inhibition assay. The [Arg25,45,56,57]
PSC-RANTES analogue has comparable potency to PSC-RANTES, and one of the oxime linked analogues, 4L-
57, has potency only 5-fold lower, with scope for improvement. Both represent promising leads for development
as microbicide compounds that could be produced at low cost via semisynthesis.
INTRODUCTION
New prevention methods are urgently required to combat the
HIV/AIDS pandemic, which is currently running at a rate of
approximately 5 million new infections per year (1). One of
the strategies currently being developed relates to the use
of “microbicides”santiviral products that can be applied topi-
cally to genital mucosa prior to sexual intercourse, thereby
preventing HIV transmission from person to person (2).
PSC-RANTES (3) is a chemokine analogue that has shown
promising efficacy in preclinical studies related to its use as a
microbicide (4). In its totally synthetic form, however, PSC-
RANTES is likely to be impossibly expensive for worldwide
use (5). Since the non-natural structures in PSC-RANTES are
all located within an N-terminal pharmacophore, semisynthetic
strategies could be envisaged in which a protein fragment
representing all but the N-terminus of the sequence is produced
by low-cost microbial fermentation, followed by site-specific
conjugation of a short synthetic peptide containing the N-
terminal pharmacophore.
One strategy to produce PSC-RANTES semisynthetically
would involve the use of native chemical ligation (6) between
a protein fragment beginning at Cys10 and an N-terminal
fragment with a C-terminal thioester that contains the noncoded
pharmacophore. We chose not to consider this route, however,
since it would involve the production of a long and relatively
expensive thioester peptide, as well as a folding step (formation
of disulfide bridges) after the ligation. Instead, we chose to focus
on approaches involving conjugation conditions that are com-
patible with the presence of the native disulfide bonds in the
protein fragment and which could be adapted to the use of
shorter, less expensive synthetic N-terminal fragments. Hence,
the first set of strategies we envisaged involved the formation
of oxime, hydrazone/hydrazide, andΨ[CH2-NH] bonds. These
require N-terminal Ser or Thr residues to be engineered into
the protein fragment (see linker-based strategy in Figure 1). With
N-terminal Ser or Thr, periodate oxidation of the amino alcohol
to a glyoxylic acid residue, O)CHsCO-, allows the specific
conjugation to an aminooxy- or hydrazide-functionalized peptide
through the formation of an oxime or hydrazone bond. In an
another linker strategy, reductive amination under slightly acidic
conditions was used to conjugate the short synthetic N-terminal
peptide fragment functionalized with an aminoacetaldehyde
moiety to the protein fragment. This approach, though less
specific because it is only based on the difference of reactivity
between R- and ε-amine groups toward aldehydes, has the
advantage of generating the shortest linkersinvolving the
substitution of only one amino acid residuesbut the disadvan-
tage of introducing a positively charged group into the protein
backbone (Scheme 1). All of the linker-based strategies lead to
modification to both the backbone and the side chains of the
* Corresponding author. Tel. +41 22 379 54 75. Fax +41 22 379
55 02.
† Present address Mintaka Foundation for Medical Research, 14
chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland.
‡ Present address ArisGen, 14 chemin des Aulx, 1228 Plan-les-
Ouates, Geneva, Switzerland.
1Abbreviations: 4L-5,7H, etc., see description of linker terminology
in the Discussion section; AOP-RANTES, the aminooxypentane oxime
of [glyoxylyl1]RANTES (2-68); Apm, aspartimide; Chg, cyclohexy-
lglycine; EDC, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide; HM-
Thiaz, 2-hydroxymethylthazolididine; MES, morpholinoethanesulfonic
acid; NHS, N-hydroxysuccinimide; NNY-RANTES, NR(n-nonanoyl)-
RANTES(2-68); PrS, thioproline; Pse, 2-(phenylsulphonyl)ethyl; PSC-
RANTES, (NR(n-nonanoyl)-des-Ser1-[L-thioprolyl2, L-cyclohexylglycyl3]-
RANTES(4-68)); RANTES, the traditional name for the chemokine
CCL5 (Swissprot: CCL5_HUMAN).
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protein at the linkage site, and some of them also change the
register of the backbone by adding atoms (Scheme 1). Hence,
we opted to create panels of analogues for each linkage
type, varying the site at which the linkage was introduced (Table
1).
Yet another possible strategy requires the protein fragment
to have N-terminal cysteine. The resulting 1-amino, 2-thiol
structure at the N-terminus can be specifically conjugated to a
glycolaldehyde-functionalized ester of the short synthetic N-
terminal fragment through formation of a thiazolidine, which
can be further rearranged to a 2-hydroxymethyl-thioproline with
the generation of an authentic peptide bond (Scheme 2). The
drawback here is that the structure of the pharmacophore unit
of PSC-RANTES cannot be precisely reproduced (see thiazo-
lidine analogue strategy in Figure 1).
Our last strategy involved direct acylation of the amino
terminus of protein fragments in which either four or five of
the five lysine residues present in native RANTES had been
replaced by arginine (see direct acylation strategy in Figure 1).
This approach has the advantage of generating a natural peptide
bond at the linker site but the disadvantage of changing
structures elsewhere in the protein that may be important for
activity.
The PSC-RANTES analogues from the different groups were
evaluated for their anti-HIV activity. We discuss the results
obtained with regard to structure–activity relationships at the
anti-HIV pharmacophore of PSC-RANTES and suggest that two
of the above strategies have potential for development as
economic routes to production of semisynthetic PSC-RANTES
analogues that could be effective microbicides.
EXPERIMENTAL PROCEDURES
Reagents and Chemicals. Unless otherwise specified, all
solvents and reagents were obtained from Fluka (Buchs,
Switzerland), were of analytical or higher grade, and were used
without further purification. All amino acids were purchased
from Orpegen (Heidelberg, Germany). The resins were from
NeoMPS (Strasbourg, France) or Bachem (Bubendorf, Swit-
zerland). Water was repurified using a Milli-Q system (Milli-
pore, Inc., Bedford, MA).
HPLC. Analytical RP-HPLC (reverse-phase high-perfor-
mance liquid chromatography) was performed using a column
250 × 4 mm i.d. packed with Nucleosil 300-A, 5 µm C8
particles. The flow rate was 0.7 mL/min, and effluent was
monitored at 214 nm. Peptides were purified on a C8 semi-
preparative column (250 × 10 mm i.d. Nucleosil 300-A, 5 µm
particle size) at a flow rate of 4 mL/min monitored at 214 nm,
or purified on a Vydac C8 preparative column (250 × 22 mm
i.d., 10 µm particle size) at 15 mL/min monitored at 214 nm.
Solvents used in RP-HPLC were as follows: A, 0.1% TFA (1
g TFA in 1 L H2O); B, 0.1% TFA in 90% acetonitrile (1 g of
TFA mixed with 100 mL of H2O and then brought to 1 L with
acetonitrile). Generally, the conditions used in analytical work
were 2 min isocratic at 20% B followed by a linear gradient to
65% B over 45 min. In preparative work, a linear gradient
(usually of the same slope) was used after 2 min at initial
conditions. All peptide components were collected manually at
the detector exit, evaporated at room temperature under reduced
pressure, frozen, and then recovered by lyophilization.
Mass Spectrometry. Electrospray ionization mass spectrom-
etry (ESI-MS) was performed in positive ion mode on a
Platform-II instrument (Micromass, Manchester, England).
Samples were introduced at 10 µL/min in solvent acetonitrile/
water/formic acid (49.9:49.9:0.2). MALDI-TOF mass spec-
trometry was performed in linear mode using sinapinic acid as
the matrix on a Voyager Elite machine (Applied Biosystems,
Foster City, CA) equipped with delayed extraction. External
calibration was performed on the electrospray machines using
a solution of horse heart apomyoglobin and on the MALDI-
TOF machine using the mixture of peptides supplied by the
manufacturer.
Synthesis of RANTES Fragments. Although the route to
bulk manufacture of the larger RANTES fragments would
ultimately be biosynthesis, for exploratory experimental pur-
poses it was more rapid and convenient to prepare them by total
chemical synthesis. The two proteins and ten protein fragments
described in Table S1 of the Supporting Information were
prepared by polymer-supported organic synthesis of the two
segments that would have been formed if they had been cleaved
between residues 33 and 34. t-Butoxycarbonyl chemistry was
used, as described in ref (7). The segments were coupled in a
native chemical ligation (6). Folding of the resulting molecule
with concomitant disulfide formation was carried out in the
presence of a Cys-SH/(Cys-S)2 redox couple except for [Cys2]-
RANTES(2-68), where conjugation to the N-terminal peptide
fragment was performed before the folding step. Purity and
integrity of the resulting analogues were routinely verified by
HPLC and mass spectrometry.
Synthesis of n-Nonanoyl Peptides. The short N-terminal
synthetic fragments that contain the pharmacophore all possess
an N-terminal n-nonanoyl group as in PSC-RANTES (Scheme
1). These n-nonanoyl peptides were synthesized as described
in ref (8). Crude material obtained after ether precipitation
(following HF resin cleavage) was used without HPLC purifica-
tion for further C-terminal functionalization. For synthesis of
n-nonanoyl-PrS-Chg-Ser-Ser-Asp6, Boc-Asp(OPse)-OH was
used to maintain side-chain protection during further C-terminal
modification of the peptide. Because of difficulties with the
deprotection, this peptide was also synthesized using Fmoc
chemistry, using 2-chlorotrityl chloride resin and cleaving the
fully protected peptide with acetic acid/trifluoroethanol/dichlo-
romethane (2:2:6) for 2 h.
Synthesis of Heterobifunctional Spacer Reagents Contain-
ing Aminooxy Groups (Scheme 3). I. 2-(Boc-aminooxy)ethy-
lamine (III). N-[2-(Tert-butyl-N-hydroxycarbamoyl)ethyl]phthal-
imide (I). Conditions of synthesis are similar to those described
in ref (9). tert-Butyl N-hydroxycarbamate (1.32 g, 10 mmol)
was dissolved in anhydrous DMF (7 mL), NaH (380 mg, 60%
dispersion in mineral oil, 9.5 mmol) was added at room
temperature, and the mixture stirred for 1 h, then cooled to 0
°C, treated with 2-bromoethylphthalimide (2.03 g, 8 mmol) for
2 h at 0 °C, and then left at room temperature overnight. The
material was precipitated in cold water (100 mL) and the
precipitate redissolved in EtOAc. The organic layer was
Figure 1. Schematic representation of the semisynthetic strategies used
in this study. PSC-RANTES (upper panel) can be considered to consist
of a protein fragment derived from native RANTES (cyan), and which
could be produced cheaply by biosynthesis, to which a short, synthetic
N-terminal pharmacophore region containing non-natural, noncoded
structures (red) is joined. All three of the semisynthesis strategies we
evaluated in this study necessitate the introduction of modifications
(indicated in gray) to the PSC-RANTES protein.
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successively washed with a saturated NaCl solution and then
water. The crude product (I) was dried over MgSO4 and solvent
removed. Yield 1.3 g (53%).
N-[2-(tert-butyl-N-hydroxycarbamoyl)ethyl]amine (III). A
mixture of 1.1 g of N-[2-(tert-butyl-N-hydroxycarbamoyl)eth-
yl]phthalimide (I) and 1.4 mL hydrazine hydrate in 20 mL
ethanol was refluxed overnight at 90 °C. The solution was
cooled, and the precipitated phthalyl hydrazide was separated
by centrifugation. The supernatant was diluted with water and
acidified with 10% TFA. A further precipitate was separated
by centrifugation and the deprotected material isolated from the
supernatant by preparative HPLC (yield 215 mg, 0.75 mmol,
21%), showing the expected mass (ESI-MS M + H found 177.2,
theor. M + H 177.0).
II. 4-(Boc-aminooxy)butylamine (IV). The same protocol was
used starting from tert-butyl N-hydroxycarbamate (400 mg, 3
mmol), NaH (114 mg, 2.85 mmol), and 4-bromobutylphthal-
imide (675 mg, 2.4 mmol). The recovered N-[4-(tert-butyl-N-
hydroxycarbamoyl)butyl]phthalimide (II) (630 mg, 1.7 mmol,
70%) was treated with a 2-fold molar excess of hydrazine
Scheme 1. Backbone Structure of PSC-RANTES Analogues Resulting from the Use of Different Linker-Based Strategies
Table 1. N-Terminal Structures of PSC-RANTES Analogues Produced Using Linker-Based Strategiesa
a The residues substituted by the linkers are indicated using ∧∧∧; the structures of the different linkers can be found in Scheme 1. See the
appropriate footnote for the abbreviations for noncoded amino acids.
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hydrate to afford, after isolation and HPLC purification as above,
an oily product (IV) (105 mg, 0.33 mmol, 19%) with the
expected mass (ESI-MS M + H found 204.8, theor. M + H
205.0).
Synthesis of Aminooxy-Functionalized n-Nonanoyl Pep-
tides. Coupling of the 2- and 4-Carbon Linkers to the
C-Termini of the n-Nonanoyl Peptides. n-Nonanoyl peptide
(25 µmol) was dissolved in 50 µL DMF and mixed with
equimolar amounts of solid NHS and diisopropylcarbodiim-
ide. A 3-fold molar excess of Boc-aminooxy-linker (III or
IV) was dissolved in 50 µL DMF and added to the
n-nonanoyl peptide solution, and diisopropylethylamine,
equivalent to a 4-fold molar excess over n-nonanoyl peptide,
was added to the reaction mixture which was then incubated
overnight at room temperature. The mixture was then
acidified with 10 µL acetic acid and the conjugation product
isolated by preparative HPLC using a gradient of 30-70%
B over 40 min. In the case of n-nonanoyl-PrS-Chg-Ser-Ser-
Asp(OPse)-OH, the (OPse) protecting group was removed
afterward by 2 h treatment at 37 °C in 3 mL of 0.1 M
NaHCO3, 10% R-mercaptoethanol, 40%CH3CN, pH 9.0 (10).
The lyophilized material was deprotected by a 5 min
treatment in 1 mL neat TFA. The TFA was evaporated under
N2, the material redissolved in CH3CN/water and freeze-dried.
Synthesis of Hydrazide-Functionalized n-Nonanoyl Pep-
tides. These were made manually at the 0.1 mmol scale
according to standard techniques of Fmoc peptide chemistry
(11) starting with 2-methoxy-4-alkoxybenzyloxycarbonyl
hydrazide resin (Bachem, Switzerland). The n-nonanoyl
peptides were deprotected and cleaved from the resin by
vortexing with 1.5 mL of a mixture consisting of TFA (95%),
2.5% H2O, and 2.5% triisopropylsilane (v/v) for 1 h at room
temperature and filtered to remove resin. The solution was
evaporated under N2, and the oily material taken up in
CH3CN-water and lyophilized. The resulting n-nonanoyl
peptides could be used in the conjugation reaction without
any further purification.
Synthesis of Aldehyde-Functionalized Reagents and n-
Nonanoyl Peptides. n-Nonanoyl-2,2′-dimethoxyethyl ester was
prepared by reaction of n-nonanoic acid cesium salt with
bromoacetaldehyde dimethylacetal in dimethylformamide (DMF)
at 60 °C for 48 h (12). n-Nonanoyl peptide (25 µmol) dissolved
in 200 µL DMF was mixed with a 5-fold excess of aminoac-
etaldehyde diethylacetal and an equimolar amount of (benzot-
riazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
(PyBOP) reagent. The solution was incubated for 3 h at room
temperature, acidified, and the conjugation product isolated by
preparative HPLC using a gradient of 30–70% B over 40 min.
The acetal group was cleaved by a 5 min treatment in 1 mL
neat TFA. The TFA was evaporated under N2, the n-nonanoyl
glycoaldehyde ester was redissolved in CH3CN/ water, freeze-
dried, and used immediately for the conjugation step. In the
case of the aldehyde derivative of the fully protected peptide,
n-nonanoyl-PrS-Chg-Ser(tBu)-Ser(tBu)-Asp(OtBu), the protect-
ing groups were removed all at once by a 1 h treatment in neat
TFA.
Conjugation through Oxime and Hydrazone Bonds. The
truncated proteins with N-terminal serine residues were dis-
solved in water at 2 mg/mL, mixed with an equal volume of
2% (w/v) NH4HCO3 buffer, containing 40 mM methionine, pH
8.3, and oxidized in the presence of a 20-fold excess of sodium
metaperiodate. After 10 min incubation in the dark, the reaction
was quenched by the addition of a 10 000-fold excess of
ethylene glycol. The oxidized protein was retained on a Sep-
Pack cartridge, eluted with 80% CH3CN in 0.1% TFA, and
freeze-dried. The protein was redissolved (4 mg/mL) in a 0.1
M acetate (Na) buffer containing 20 mM methionine, 40%
CH3CN, apparent pH 4.6, and either a 2-fold excess of
aminooxy-functionalized n-nonanoyl peptide or a 6-fold excess
of hydrazide-functionalized n-nonanoyl peptide was added,
dissolved in the same buffer at a concentration of 4 mg/mL.
After overnight incubation, the conjugation product was isolated
by semipreparative HPLC, using a 1 × 25 cm Macherey-Nagel
column at 4 mL/min. In the case of hydrazone conjugates, the
hydrazone bond could be reduced by incubation of the recovered
and lyophilized material in 400 µL of 0.4 M NaBH3CN in the
same buffer as used previously for 4 days in the dark (13), before
HPLC purification.
Conjugation through a Thiazolidine Analogue. Unfolded
[Cys2]RANTES(2-68) was dissolved in 0.1 M sodium phos-
phate, 6 M GnCl, pH 6.0, to a concentration of approximately
5 mg/mL, a 50 molar excess of freshly TFA-deprotected
n-nonanoyl glycolaldehyde ester was added and the pH read-
justed to 5.0. After a 1 h incubation, the conjugation product
was isolated by preparative HPLC and freeze-dried. The
thiazolidine conjugate was then redissolved in 0.1 M sodium
phosphate, 6 M GnCl, pH 7.5, at 4 mg/mL and the solution
incubated for 4 days at 37 °C, with daily readjustment of the
pH to 7.5. The solution was acidified to pH 3.0 and further
incubated with 5 mg tris(2-carboxyethyl)phosphine for 1 h,
before isolation of the rearranged thiazolidine analogue by
Scheme 2. Ligation through Thiazolidine Ring Formation
Scheme 3. Synthesis of Heterobifunctional Spacer Reagents
Containing Aminooxy Groups
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semipreparative HPLC. The material was then refolded under
the same conditions as given above.
Conjugation through a Methylene Amino, Ψ[CH2-NH]
Bond. Truncated RANTES (2 mg/mL in water) was reacted at
a molar ratio of 1:10 with 5 mg/mL solution freshly deprotected
n-nonanoyl aminoacetaldehyde peptide in 80% acetonitrile and
mixed with an equal volume of 0.2 M acetate(Na) buffer
containing 50% acetonitrile, pH 5.2. The reaction took place at
room temperature for 15 h. Sodium cyanoborohydride (1 M)
dissolved in the same buffer was added to the reaction to a final
cyanoborohydride concentration of 0.3 M. The reaction medium
was further incubated at room temperature for at least 6 h before
isolation of the conjugation product by semipreparative HPLC.
Conjugation via N-Terminal Acylation of Protein
Fragments in Which Lysine Residues Had Been Replaced
by Arginines. The complementary short N-terminal peptide,
n-nonanoyl-PrS-Chg, was activated with NHS by a 1 h
incubation with equimolar amounts of HO-Su and EDC in
DMSO. The modified protein fragment, [Arg25,45,56,57] RANTES-
(4–68) (see Table S1 in the Supporting Information), was
dissolved in 0.1 M MES buffer containing 50% DMSO, apparent
pH 5.5, to a concentration of approximately 4 mg/mL, a 20
molar excess of freshly activated peptide was added, and the
solution stirred over 15 h. The solution was then acidified with
acetic acid, diluted 10-fold with water, and the conjugation
product isolated by semipreparative HPLC using a 1 × 25 cm
Macherey-Nagel column at 4 mL/min.
HIV Entry Inhibition Assay. Envelope-mediated cell fusion
assays were carried out as described in ref (14) with HeLa-P5L
(15) and HeLa-Env-ADA (16) cell lines. Experiments were
performed in triplicate, and dose-inhibition curves were fitted
by using Prism software (GraphPad, CA).
RESULTS
Production of Oxime Analogues. Construction of the oxime
analogues was driven by the idea of synthesizing the shortest
possible stable linker, functionalized with an amine and an
aminooxy group. Our initial strategy involved using a one-
carbon linker, which would have entailed the replacement of
only two residues and would have kept the backbone of the
semisynthetic protein in register with that of PSC-RANTES
(Scheme 1). However, these compounds proved inaccessible
due to their high instability (data not shown), and it was
therefore necessary to investigate linkers with two or more
carbon atoms. As shown in Scheme 1, incorporation of a two-
or four-carbon linker results in the replacement of two or three
residues, respectively. While the two-carbon linker has the
advantage of substituting one less residue that the four-carbon
linker, it has the disadvantage of introducing a one-atom shift,
relative to PSC-RANTES, of the register of the backbone of
the N-terminal region of the semisynthetic protein (Scheme 1).
Since it is likely that linker position will influence the biological
activity of the resulting protein, we opted to generate a panel
of analogues for each linker, moving the site of the linker within
the N-terminal region of the protein. The nomenclature used
for this series of analogues was 2L-x,y for the two-carbon linker
and 4L-x,y for the four-carbon linker, with x and y denoting
the positions of the first and last substituted residue (Table 1).
We chose to produce the aminooxy-functionalized n-nonanoyl
peptides through reaction of N-(bromoalkyl)phthalimides with
tert-butyl N-hydroxycarbamates. A 2-fold excess of aminooxy-
functionalized peptide was sufficient to drive the conjugation
reaction to completion. All intermediates in the construction of
the different conjugates were characterized by mass spectrometry
and described in Table S1 in the Supporting Information.
Production of Hydrazone and Hydrazide Analogues. We
used 2-methoxy-4-alkoxybenzyloxycarbonyl-hydrazide resin to
produce a range of n-nonanoyl peptides hydrazide-functionalized
with a two-carbon linker. These could be reacted with N-
terminal Ser or Thr protein fragments that had been oxidized
with periodate to generate a range of hydrazone-linked PSC-
RANTES analogues. Reduction of the hydrazone bond with
NaBH3CN gave us easy access to the corresponding methyl
hydrazine linked analogues, which allow more backbone flex-
ibility at the linkage site. The nomenclature used for this group
of compounds is 4L-x,yH for the hydrazone analogues and 4L-
x,yHR for the reduced methyl hydrazine analogues, with x and
y denoting the positions of the first and last substituted residue
(Table 1).
Production of Ψ[CH2-NH] Analogues. Reductive amina-
tion, in which an aldehyde reacts with the N-terminal R-amino
group of a target protein in the presence of sodium cyanoboro-
hydride as a reducing agent, has been recently explored as a
route to selectively modify proteins at the R-amino group
without protecting the -amino groups on lysine residues (17–19).
This approach is less restrictive than other established semi-
synthetic strategies, since it does not require the presence of an
N-terminal residue such as Ser, Thr, or Cys. Under only slightly
acidic conditions, the R-amino group (pKa in the region of 8) is
deprotonated to a significantly greater extent than the -amino
groups of lysine residues (pKa in the region of 10). Reaction of
a peptide aldehyde with the R-amino group results in the
replacement of one residue in the peptide chain by an amino-
ethylene moiety (Scheme 2).
We opted to test this conjugation approach using the same
group of protein fragments that was used to generate the oxime
and hydrazone analogues, together with a corresponding group
of aminoacetaldehyde-conjugated n-nonanoyl peptides. The
nomenclature used for this series of analogues was 1L-x, with
x and y denoting the positions of the substituted residues (Table
1). It was necessary to change the strategy for the functional-
ization of one of the n-nonanoyl peptides, namely, n-nonanoyl-
PrS-Chg-Ser-Ser-Asp(OPse)-OH, since the Asp deprotection
step carried out under basic conditions resulted in an almost
quantitative dehydration of the compound with the formation
of an aspartimide. While we opted to retain the n-nonanoyl
peptide carrying the aspartimide modification and use it to
produce an extra analogue (1L-7 des, Table 1), it was possible
to obtain the desired Asp analogue by using the orthogonal
(OtBu) protecting group for the Asp side chain, with the fully
protected peptide being cleaved from the 2-chlorotrityl chloride
resin with acetic acid.
Not unexpectedly, given the limited selectivity of the ap-
proach, each conjugation reaction gave rise to detectable
overreaction products resulting from the conjugation of the
aminoacetaldehyde-functionalized n-nonanoyl peptides with the
-amino groups of the protein (Figure 2).
Production of Thiazolidine Analogues. Proteins carrying
an N-terminal cysteine residue can be site-specifically modified
at the N-terminus with an aldehyde under acidic conditions (20),
and the use of a glycolaldehyde ester opens the way to a
rearrangement that regenerates a true peptide bond (21), although
both the condensation and rearranged products give a mixture
of two diastereoisomers due to the creation of a new asymmetric
carbon at position 2 of the thiazolidine ring. We chose to use
this approach to generate two PSC-RANTES analogues. First,
conjugation of an n-nonanoyl glycolaldehyde ester to [Cys2]-
RANTES(2-68) generates as the final product NRn-nonanoyl-
[2-hydroxymethythiazolidine2]RANTES(2-68), an analogue very
similar in structure to NR(n-nonanoyl)-RANTES(2-68), the
molecule known as NNY-RANTES. This was a lead compound,
already quite potent in itself, identified during the development
of PSC-RANTES (3). Second, since the technology developed
by the group of Schultz (22) enables a single noncoded amino
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acid to be site-specifically incorporated into recombinant
proteins and works particularly well with aromatic or cyclic
residues, we opted to perform the same reaction on [Cys2,
Chg3]RANTES(2-68), in order to produce the analogue NR(n-
nonanoyl)-[2-hydroxymethylthazolididine2, Chg3]RANTES(2-
68), an analogue for which the only structural difference relative
to PSC-RANTES is a hydroxymethyl side chain (present in two
diastereisomeric forms) on the carbon at position 2 of the
thiazolidine ring. If the latter analogue were found to have useful
biological properties, the methods of Schultz and co-workers
could presumably be adapted to the production of the [Cys2,
Chg3]RANTES(2-68) as a totally recombinant molecule, onto
which, as we have just seen, the n-nonanoyl 2-hydroxymethyt-
hazoline moiety could be introduced with total site specificity.
For the purposes of this part of the study, the folding of the
protein with concomitant formation of disulfide bridges was
performed after conjugation of the peptide to enable us to avoid
the need to develop the new folding conditions for totally
synthetic protein fragments carrying an N-terminal cysteine
residue. For both conjugation reactions, incubation with a 50-
fold excess of the n-nonanoyl glycolaldehyde ester resulted in
an HPLC shift of the protein of more than 8 min, as shown in
Figure 3A for the [Cys2, Chg3]RANTES(2-68). The isolated
thiazolidine ester derivatives were resolubilized in a sodium
phosphate buffer pH 7.5 to allow O to N acyl rearrangement,
as previously described (21). This reaction was stopped after 4
days of incubation (Figure 3C), since no improvement could
be observed over a longer period of time (data not shown). The
incomplete reaction may be related to the presence of contami-
nating n-nonanoyl glycolaldehyde ester, which is difficult to
detect and totally eliminate after the first reaction step due to
its very low optical absorbance, and which would be highly
reactive with the protein’s -amino groups under the more basic
conditions of the second reaction. Starting with 15 mg unfolded
protein, 5 mg of condensation product were isolated, which
finally gave 1 mg of the rearranged compound.
Anti-HIV Activity of PSC-RANTES Analogues. The anti-
HIV activity of the full set of PSC-RANTES analogues, together
with reference compounds AOP-RANTES, NNY-RANTES, and
PSC-RANTES, was determined in a series of cell fusion assays.
Each compound was assayed in at least four independent
experiments, with PSC-RANTES used as an internal standard
in each experiment. Results are shown in Figure 5. The
measured potency of PSC-RANTES across the total of 41
independent assays (mean IC50 value of 24 pM) is in agreement
with previously published values (3), as are those for AOP-
RANTES and NNY-RANTES (mean IC50 values of 0.96 nM
and 190 pM, respectively).
Oxime-Based Analogues. In general, the oxime-based ana-
logues with two-carbon linkers were less potent than the
corresponding analogues with four-carbon linkers (both 2L-45
and 2L-56 are less potent than 4L-46; both 2L-56 and 2L-67
are less potent than 4L-57; both 2L-67 and 2L-78 are less potent
than 4L-68). While a number of the analogues in this series
show anti-HIV activity that compares well to the earlier lead
molecules, AOP-RANTES and NNY-RANTES, the best ana-
logue in this series, 4L-57 (IC50 value of 130 pM), is still
approximately 5-fold less potent than PSC-RANTES.
Hydrazone/Methyl Hydrazine-Based Analogues. Each of
the hydrazone analogues showed comparable (4L-46H) or lower
Figure 2. Analytical HPLC of the reductive amination reaction of
n-nonanoyl-PrS-Chg-Ser4-NH-CH2-CHO with [Asp6]RANTES(6-68).
(A) Reaction mixture 2 h after addition of NaBH3CN following an
overnight incubation. (B) Reaction mixture 20 h after addition of
NaBH3CN. (C) n-Nonanoyl-PrS-Chg-Ser4-NH-CH2-CH2-RANTES(6-
68), after semipreparative HPLC purification. Peak 1, [Asp6]RANTES(6-
68); Peak 2, the formed conjugate, n-nonanoyl-PrS-Chg-Ser4-NH-CH2-
CH2-RANTES(6-68); Peak 3, excess n-nonanoyl-PrS-Chg-Ser4-NH-
CH2-CHO; Peak 4, the overreaction bisubstituted conjugate.
Figure 3. Progress in the construction of n-nonanoyl-HMThiaz2-Chg3-
RANTES(4-68). (A) Reaction of [Cys2, Chg3]RANTES(2-68) with
n-nonanoyl glycolaldehyde ester after 45 min incubation at pH.5.0.
(B,C) The O to N acyl transfer at pH 7.5 after 1 and 4 days incubation
at 37 °C, respectively. Peak 1, [Cys2, Chg3]RANTES(2-68); Peak 2,
the thiazolidine conjugate; Peak 3, the O,N acyl rearranged conjugate;
Peak 4, the hydrolyzed condensation product [HMThiaz2,
Chg3]RANTES(2-68).
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activity (4L-57H, 4L-68H) to the corresponding four-carbon
linker oxime analogues. Reduction to methyl hydrazide did not
affect the activity of two of the analogues (4L-57HR, 4L68HR),
but strongly reduced the activity of a third (4L-46HR).
Ψ[CH2-NH] Analogues. The use of the reductive amination
approach gave us access to a one-carbon linker strategy, which
has the advantages of retaining backbone register while requiring
replacement of only one residue. Interestingly, this strategy
provided little advantage over the four-carbon linker oxime
approach, which also retained backbone register but necessitated
the replacement of three residues. While 1L-4 shows slightly
higher potency than 4L-46, 1L-5 was less potent than any of
the 4L oxime compounds, 1L-6 showed lower potency than 4L-
57, and 1L-7 showed lower potency than both 4L-57 and 4L-
68.
Thiazolidine Analogues. The protein NR(n-nonanoyl)-
[HMThiaz2]RANTES(2-68) shows considerable anti-HIV activ-
ity (IC50 value of 120 pM), a value comparable to that of our
earlier lead compound, NNY-RANTES, to which it has a strong
structural resemblance (see Discussion section). When in
addition to the substitution of 2-hydroxymethyl thiazolidine for
Pro2 we replaced Tyr3 by cyclohexylglycine, the potency of the
new analogue was less (IC50 value of 0.98 nM) by an
approximately 40-fold reduction compared to the lead compound
PSC-RANTES in spite of the close structural resemblance of
the two proteins.
“All-Arg” Analogues. If the protein fragment were to contain
no lysine residues, acylation by the short N-terminal fragment
would be totally site-specific onto the R-amino group of the
protein fragment. This could be achieved by replacing all the
lysine residues in the native sequence of the protein fragment
(positions 25, 33, 45, 56, and 57) with arginine. Had the
properties of the resulting protein [Arg25,33,45,56,57]PSC-
RANTES been as attractive as those of PSC-RANTES itself, it
might well have led to a highly economic production process,
in spite of the noncoded residues. However, upon synthesis and
testing of this analogue, we found that, despite its having an
N-terminal region identical to that of PSC-RANTES, it has an
approximately 15-fold reduction in potency relative to PSC-
RANTES (Figure 5, IC50 value of 380 pM). This prompted us
to speculate that one or more of the lysine residues in the protein,
although distant in the linear sequence of the protein from its
putative pharmacophore, may play an important role in its anti-
HIV activity. On the basis of ongoing studies of a different group
of PSC-RANTES analogues (23), as well as studies in which
Lys residues of native RANTES were substituted (24), we
postulated that Lys33 might be a key component of the PSC-
RANTES pharmacophore. We found, in agreement with this
hypothesis, that [Arg25,45,56,57]PSC-RANTES showed potency
indistinguishable from that of PSC-RANTES (IC50 value of 35
pM). It was therefore desirable to see if, despite the presence
of one -amino group in the relevant protein fragment as well
as the R-amino group, acylation by the short N-terminal peptide
Figure 4. Production of PSC-RANTES[Arg25,45,56,57] via direct acy-
lation of [Arg25,45,56,57]RANTES(4-68) with n-nonanoyl-PrS-Chg.
Analytical HPLC of the reaction medium after 15 h incubation at room
temperature (A) and after isolation of the conjugation product (B). Peak
1, unreacted [Arg25,45,56,57]RANTES(4-68); Peak 2, PSC-RANTE-
S[Arg25,45,56,57]; Peak 3, excess n-nonanoyl-PrS-Chg. Peak 4 is
presumed to be the product of over-reaction, with acylation of both
the R- and -amino groups of the protein fragment.
Figure 5. Anti-HIV potency of semisynthetic PSC-RANTES analogues and reference compounds. At least four independent dose–response experiments
were performed for each compound using a cell fusion assay, Bars represent the mean potency from the group of experiments performed
(pIC50; -log(molar IC50 value)), with error bars representing the SEM. See text for the definition of the linker nomenclature. HMThiaz2 ) NR(n-
nonanoyl)-[HMThiaz2]RANTES(2-68), HMThiaz2-Chg3 ) NR(n-nonanoyl)-[HMThiaz2, Chg3]RANTES(2-68).
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could be directed to the R-amino group alone by an appropriate
choice of reaction conditions (see below).
Production of Analogues by N-Terminal Acylation of
Protein Fragments Having No, Or Few, Lysines. The
satisfactory potency of [Arg25,45,56,57]PSC-RANTES, mentioned
above, led us to consider a pH-controlled acylation of the
R-amino group of [Arg25,45,56,57]RANTES(4-68) with n-nonanoyl-
PrS-Chg to produce the full-length construct. The reaction had
to be performed in a semiorganic medium to solubilize the
highly hydrophobic N-terminal peptide. DMSO turned out to
be the most appropriate cosolvent for this reaction, leading to
the formation of the wanted product, eluting at approximately
35 min (Figure 4A). The other solvents investigated (DMF,
THF) resulted in the formation of a double peak in this region
(data not shown). However, even in DMSO, while the higher
reactivity of the R-amino group was clearly responsible for a
high yield of the wanted product, under the reaction conditions
investigated there was some formation of overreaction products,
eluting at approximately 44 min (Figure 4A).
DISCUSSION
In this study, we set out to identify strategies with potential
for development as economical routes to production of a PSC-
RANTES analogue with antiviral activity as close as possible
to that of the parent protein. The bulk of the protein would be
produced at low cost by biosynthesis prior to attachment to a
short N-terminal pharmacophore region that contains the non-
natural, noncoded structures and which would be synthesized
separately. High-yield production of recombinant RANTES
fragments has been demonstrated using E. coli with expression
methods directed toward inclusion body formation (24), and
we have successfully used this approach to produce samples of
N-terminally truncated derivatives of RANTES (O.H. et al.,
unpublished results). While expression of proteins via inclusion
body formation often leads to incomplete cleavage of the
initiating methioine (e.g., ref 25), this problem can be overcome
by the use of N-terminal peptide tags featuring specific
enzymatic cleavage sites (e.g., ref 26). The criteria we chose to
adopt when exploring the suitability of the different ligation
strategies were as follows: ease and cost of production of the
N-terminal fragment, ease and yield of the conjugation reaction,
and anti-HIV activity of the resulting analogue. These consid-
erations led us to decide not to explore semisynthesis of PSC-
RANTES via native chemical ligation; while it would certainly
be a feasible approach, it would necessitate the production of a
long and relatively expensive thioester peptide, as well as a
folding step after the ligation.
We therefore considered several semisynthesis approaches,
some of which necessitate the introduction of a nonpeptide linker
region into the protein. Since incorporation of the linker leads
to the replacement of backbone and side chain atoms of the
protein, and the likelihood of inactivation of a protein increases
with the number of substitutions introduced into key regions,
we attempted to keep the linkers as short as possible. We varied
the site of introduction of the linker, and hence the site at which
atoms of the original protein would be changed.
Taken together, study of the three linker-based strategies that
we used shows that certain parts of the N-terminal region would
appear to be more amenable to the introduction of linker
moieties than others. We found overall that substitution at
positions 4 and 8 led to a greater reduction in biological activity
than substitution at positions 5, 6, and 7. Finally, we did not
find that use of a shorter linker necessarily leads to better
retention of activity. Indeed, the most potent protein that we
constructed with a linker, the oxime-linked analogue 4L-57, has
the longest linker region tested, one which requires three residues
to be replaced. This four-carbon oxime linker performed
generally better than the shorter two-carbon linker that we tested,
perhaps because the two-carbon linker modifies the backbone
register of the semisynthetic protein with respect to PSC-
RANTES.
It was not our purpose in this exploratory study to completely
optimize the processes evaluated. In the case of the four-carbon
linkers, a useful next step might be to use molecular diversity
(library) methods to change the pharmacophore: it is possible
that changes there could offset the effect of the linker on activity.
It was possible to directly compare the four-carbon linker
oxime linkage strategy with the corresponding one using
hydrazones. The activity of the hydrazone analogues was
generally lower than that of the corresponding oxime ones,
indicating that the activity of the protein is influenced by either
the composition or flexibility of the linkers, or both. Reducing
the hydrazone linker to methyl hydrazide would be expected to
increase linker flexibility, and at certain positions in the protein,
this led to a slight increase in activity. In the case of 4L-46HR,
however, reduction to a hydrazide led to a more than 10-fold
loss in potency. This loss might be related to the fact that in
this case the secondary -NH- group in the reduced linker could,
when ionized, place a positive charge in proximity to the
negative charge of the Asp6 side chain in the native protein
and a strong ionic interaction here might distort the configuration
of the whole pharmacophore.
Further evidence that introduction of a positive charge into
the backbone can affect activity is provided by results obtained
with Ψ[CH-NH] analogues. While these analogues have the
shortest linker region that we tested, one which requires
the replacement of only one residue, they introduce a full
positive charge into the backbone, since reduction of the Schiff
base results in a secondary amine with a pKa in the 10.0–11.0
range. Once again, 1L-5, the analogue in theΨ[CH2-NH] series
in which the backbone charge is introduced adjacent to Asp6,
shows the greatest reduction in activity. The highest activity in
this series of conjugates was obtained for 1L-6, which means
that replacement of Asp6 by an aminoethylene moiety with
concomitant alkylation of the nitrogen of Thr7 is better tolerated.
Overall, however, the performance of the Ψ[CH2-NH] ana-
logues suggests that use of a cumbersome but uncharged linker
region does less harm to activity than introduction of a shorter
linker carrying a positive charge.
Ligation According to Tam’s Thiazolidine Strategy. This
method (21) yields a native peptide bond in the backbone
structure with, however, the introduction of a hydroxymethyl
thiazolidine residue immediately C-terminal to the junction site.
This residue can be thought of as an analogue of proline (present
at position 2 of RANTES and of the earlier lead protein NNY-
RANTES) and of thioproline (present at this position in the
current lead PSC-RANTES). We therefore used the strategy to
incorporate 2-hydroxymethyl thiazolidine at position 2 of NNY-
RANTES, and it was encouraging to find that it retains the
potency (IC50 value of 120 pM) of the parent molecule. We
also produced a 2-hydroxymethyl thiazolidine2 analogue of our
best protein lead PSC-RANTES using the same chemistry. This
time the protein fragment was [Cys2-Chg3]RANTES(2-68),
which should be possible to obtain in recombinant form using
the Schultz technology (22). The conjugation was successful,
but the resulting molecule exhibited a significant loss of activity
(IC50 value of 0.98 nM) compared to the parent PSC-RANTES
(IC50 value of 24 pM). This apparently paradoxical result recalls
previous observations that certain modifications at position 3
of RANTES analogues that are normally beneficial lead to a
significant loss in potency when made in the presence of
normally beneficial or neutral changes at position 2 (3). Thus,
PSC-RANTES itself is the result of simultaneously replacing
Pro2 of NNY-RANTES ((NR(n-nonanoyl)-des-Ser1-RANTES(2-
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68)) with thioproline and Tyr3 by cyclohexylglycine. Substitu-
tion of position 2 alone in NNY-RANTES had given only a
slight improvement in potency, substitution of position 3 alone
had given a 3.4-fold improvement, while in PSC-RANTES
substitution of both together gave a 5-fold improvement.
However, if position 2 was substituted by 4-hydroxyproline,
which also gave no significant change in potency if introduced
alone into NNY-RANTES, the simultaneous introduction of
cyclohexylglycine in position 3 led neither to an improvement
nor to the maintenance of potency, but to an approximately 100-
fold decrease (3).
All-Arg Analogues. Had [Arg25,33,45,56,57]PSC-RANTES (in
which all the lysines in the sequence are replaced by arginines)
shown comparable activity to PSC-RANTES itself, it would
have been possible to use the short N-terminal pharmacophore
peptide to acylate with complete specificity the sole amino group
of the corresponding protein fragment, namely, the R-amino
group. Unfortunately, it showed a significant loss in activity
relative to PSC-RANTES. However, [Arg25,45,56,57]PSC-
RANTES showed activity comparable with that of PSC-
RANTES, confirming earlier indications as to the importance
of Lys33 for the anti-HIV activity of PSC-RANTES (23).
[Arg25,45,56,57]PSC-RANTES therefore represents a potent can-
didate molecule that could be produced by semisynthesis given
sufficient selectivity of acylation between the protein fragment’s
one R-amino group and its one -amino group. In an initial
practical test of this strategy, we obtained a sufficient degree
of selectivity to offer the hope that optimization might lead to
a practically useful process. We would not expect the replace-
ment of the four lysines by arginine to increase the immuno-
genicity of the protein, but this point would need to be
investigated experimentally.
We conclude that, in particular, both the four-carbon oxime
linker and the direct acylation of [Arg25,45,56,57]RANTES (4-
68) represent routes to powerful semisynthetic anti-HIV com-
pounds that show potential for optimization.
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Abstract: The small GstI protein (63 amino acids) of Rhizobium leguminosarum is the endoge-
nous inhibitor of the glnII (glutamine synthetase II) gene expression. It has been suggested that GstI
has a predominantly b-structure and mediates the block of translation and stabilization of glnII
mRNA through direct binding to its 50 untranslated region. Because of the unavailability of
adequate amounts of puriﬁed recombinant protein, the mechanism as well as the protein tridimen-
sional structure remain very poorly understood. To obtain the full-length protein, we have under-
taken the chemical synthesis of the protein by different approaches. In a ﬁrst attempt, the stepwise
synthesis was unsuccessful, with strong aggregation experienced on the N-terminal side, after resi-
due 44 from the C-terminus. In a second approach, we set up the conditions to carry out a native
chemical ligation (NCL). Albeit the protein contains two Cysteine residues, located at positions 40
and 47, to minimize the size of the N-terminal segment to be synthesized, we have devised an alter-
native strategy of ligation on Met32, utilizing homoCys as the ligating moiety and then alkylating
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the resulting polypeptide with methyl iodide. New conditions to quantitatively methylate thiol groups
in complex polypeptides have been conceived, obtaining the protein in very good yields and purity. A
CD spectroscopy investigation has revealed that the protein does not adopt canonical secondary
structures but is very rich in b-structure (* 60%), in agreement with a previous study carried out on
samples obtained by recombinant methods. # 2006 Wiley Periodicals, Inc. Biopolymers 83: 508–
518, 2006
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INTRODUCTION
The small protein Glutamine synthetase translational
Inhibitor (GstI, 63 amino acids) of Rhizobium legu-
minosarum inhibits the expression of the glnII (gluta-
mine synthetase II) gene, providing one of the con-
trol mechanisms of bacterial ability to assimilate
nitrogen.1 A primary control is determined by the
nitrogen transcriptional regulator, NtrC,2 that directly
activates glnII and represses gsti, which is found
upstream of glnII and is transcribed divergently with
respect to glnII. It has been suggested that GstI medi-
ates a block of translation and stabilization of glnII
mRNA through direct binding to its 50 untranslated
region, but this mechanism remains to be eluci-
dated.1,2 Remarkably, when expressed in the heterol-
ogous background of Escherichia coli, the protein
appeared particularly sensitive to proteolytic degrada-
tion in the very N-terminal part, suggesting a high
chain ﬂexibility and thus a poorly deﬁned structure
in this protein region. A mutational analysis (alanine-
scanning) carried out on the entire protein sequence
has also indicated the residues essential for glnII
expression inhibition, which are T3, T11, Y13, Q14,
F15, V17, K18, R21, N22, M32, E33, E35, Y49,
H50, R55, and S63.3 Recombinant protein prepara-
tions from E. coli have been obtained by a combina-
tion of diaﬁltration and gel ﬁltration techniques in
the presence of a cocktail of protease inhibitors and a
preliminary analysis has shown that GstI has a mono-
meric, prevailingly -structure, as described for other
single-stranded RNA binding motifs.3
The reported difﬁculties in obtaining the full-length
protein by recombinant methods and the need for
adequate amounts to carry out new investigations on
protein structure and activity have led us to undertake
the chemical synthesis of the protein by different
approaches. In a ﬁrst attempt, the stepwise synthesis
were unsuccessful, with strong aggregation experi-
enced after residue 44 from the C-terminus. In a second
approach, we set up the conditions to carry out a native
chemical ligation (NCL).4 NCL is a very elegant and
straightforward approach that has enormously broad-
ened the beneﬁts of solid phase synthesis,5,6 opening
the route to the preparation of small to medium size
proteins by chemical methods.6 Albeit the protein con-
tains two Cysteine residues, they are located in position
40 and 47; therefore, to minimize the size of the N-
terminal segment that had to be synthesized, we de-
vised an alternative strategy of ligation on Met32 uti-
lizing homoCys as the ligatingmoiety and then methyl-
ating the resulting polypeptide with MeI.7,8 Thus far,
homocysteine has been rarely utilized in ligation reac-
tions,7 thus kinetic and thermodynamic details are
poorly understood. However, the presence of an addi-
tional methylene group would probably affect reaction
rates and yields, as the six-membered ring of the inter-
mediate homocysteinyl thioester4,6 could less favor-
ably undergo the proximity-driven S- to N-acyl migra-
tion to form a homocysteinyl amide bond. We have
prepared the protein that was then characterized by an-
alytical techniques to assess the formation of the
desired amino acid and by CD spectroscopy to investi-
gate the secondary structure of the native protein.
RESULTS AND DISCUSSION
Protein Synthesis and Characterization
A strategy for the chemical synthesis of the small, 63-
amino-acid-long GstI protein (Figure 1) has been
designed to overcome the difﬁculties associated with
the heterologous expression in bacterial hosts. Though
the synthesis of a 63-residue polypeptide falls well
within the actual limits of the stepwise solid phase
method, we observed an extensive aggregation after
assembling the ﬁrst 44 amino acids starting from the
C-terminus (see Supplementary Material S1). Aggre-
gation persisted even when coupling and deprotection
time were extended and when a variety of common
coupling reagents and solvents were used (not shown).
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The new strategy, depicted in Scheme 1, contemplates
the chemical synthesis of two fragments of similar
size, which are then ligated using the NCL method on
the Leu31-Met32 site. The ligation reaction is
achieved by means of a N-terminal homoCys residue
that is subsequently converted into a native methio-
nine by an alkylation reaction with methyl iodide.7
Cysteines on positions 40 and 47 have been oppor-
tunely protected with acetamidomethyl (Acm) until al-
kylation on position 32 is achieved. homoCys32-GstI
[32–63]Gly-Cys(Acm40,47) (product II in Scheme 1)
has been obtained by coupling ﬂuorenylmetoxycar-
bonyl (Fmoc)-L-homoCys(Trt)-OH to GstI[33–63]Gly-
Cys(Acm40,47). A glycine residue has been added to
the C-terminal end of the polypeptide to reduce the
risks of racemization by coupling the ﬁrst amino acid
to resin. After Fmoc removal and cleavage from the
resin, the polypeptide has been puriﬁed to homogene-
ity and characterized by LC–MS before its use in the
subsequent reactions. Fragment 1–31 has been suc-
cessfully prepared as a C-terminal thioester by solid
phase peptide synthesis following several alternative
approaches. Direct synthesis on a TAMPAL resin9–11
by Boc chemistry, followed by RP–HPLC puriﬁcation,
provided a highly pure product with the expected MW
(Exp./Theor.: 4048.2 6 0.2 /4047.9 amu). Ethanethiol
or Fmoc-Cys-NH2 C-terminal thioesters of the same frag-
ment were also successfully prepared using an Fmoc
chemistry-based approach. In this case, the fully pro-
tected 1–31 peptide was produced using a chlorotrityl-
chloride resin and quantitatively converted in solution
to the corresponding thioesters, in about 12 h, by using
PyBOP/diisopropylethylamine (DIEA) in DCM and a
large excess of thiols.12 Conversion of carboxylic acids
into the correponding thioesters using these conditions
reportedly occurs with low levels of racemization.12,13
These thioesters showed reactivities toward the homo-
cysteine on the N-terminus of the 32–63 fragment that
are comparable to those of the thioester I (not shown).
However, given the availability of larger amounts, this
latter derivative was used to produce the ligated pro-
tein. GstI[1–31]-COS(CH2)2-CO-Leu-COOH (I) and
homoCys32-GstI[1–63]Gly-Cys(Acm40,47) (II) reacted
in about 16 h (see Figure 2) to give the expected 64-
residue-long polypeptide, homoCys32-GstI[1–63]Gly-
Cys(Acm40,47) (III), with an average ﬁnal 60% con-
version yield based on the initial limiting thioester
reagent. A reaction side product was detected in this
FIGURE 1 Primary sequence of the 63 amino acid protein GstI. The methionine 32 lies exactly
in the middle of the sequence. The peptide 31–34, obtainable by trypsin digestion and containing
the internal methionine is underlined. Cysteines 40 and 47, protected with Acm until the last syn-
thetic step, are also shown. A C-terminal glycine has been added for synthetic convenience.
SCHEME 1 Synthetic steps required for the assembling of GstI[1-63]-Gly. (I) 200 mM phosphate
buffer, 6 M guanidinium hydrochloride, 1% thiophenol, pH 7, 12 h, RT. (II) 100 mM bicarbonate
buffer, 10% DMF, 5 mM TCEP, 0.1MMeI; 1 min, RT, then 1M DTT added. (III) AgOTf/HCl/DTT.
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reaction, whose MW corresponds to unreacted
GstI[1–31] -mercaptoethanol (-Me) thioester that
forms upon addition of the reducing agent. The pres-
ence after 16 h of unreacted GstI[1–31] suggests that
the ligation reaction with the homocysteine is less ef-
ﬁcient than with cysteine. Indeed, the same reaction
carried out using Cys32-GstI[32–63]-Gly went to
completion within the same time interval (see Sup-
plementary Material S2). Starting from about 2 mol
of thioester, about 7 mg of crude ligated polypeptide
were recovered, which, after puriﬁcation, were fur-
ther reduced to about 4 mg. The puriﬁed polypeptide
was subsequently alkylated to obtain the native
Met32 protein with the two Acm protections still
attached. Previous reports have suggested the use of
reagents such as methyl p-nitrobenzene sulphonate or
the same methyl iodide utilized in this work. Never-
theless, following these approaches7,8 to our poly-
peptide, we have observed a large set of side products
derived by unwanted hypermethylation on other re-
active residues. In our hands, neither the full-length
polypeptide nor other less complex model peptides
underwent a satisfactory methylation under the sug-
gested conditions.7,8 Indeed, the starting compounds
were recovered mostly hypermethylated after the
treatment. Under the newly devised conditions, we
made use of the highly reactive methyl iodide in very
large excess over the thiol group, which was main-
tained in the fully reduced state by the presence of the
thiol-free Tris(2-carboxyethyl) phosphine (TCEP)
reagent. In 1 min, the reaction was complete and the
polypeptide appeared not to be contaminated by side
products. By monitoring the reaction for the subse-
quent 30 min, we observed that, up to 5 min, no side
reactions occurred. Thereafter, other +14 amu and
+15 amu derivatives were readily produced, corre-
sponding to undesired methylations. The +14 amu
side products possibly derived from methylation of
lysines and appeared more hydrophobic upon RP–
HPLC analysis, whereas, the +15 derivatives, likely
due to oxidation of methionines, were eluted slightly
earlier. In our conditions, that is, 100 mM carbonate
buffer, pH 8.0, containing 5 mM TCEP, the methyla-
tion with MeI proceeded smoothly in about 1 min
with quantitative conversion to the desired product
(see Figure 3A–C). A very clean product, with the
expected MW was detected by LC–MS analysis
(Exp./Theor.: 7530.8 6 0.5/7530.47 amu). The
highly reactive reagent was then readily quenched by
the addition of a large excess of DTT. Attempts to
carry out the reaction with a smaller excess of MeI
demonstrated that the conversion required extended
reaction times leading, by consequence, to many side
products. The polypeptide was puriﬁed to homogene-
ity by RP–HPLC (3 mg recovered) and submitted to
an extensive characterization by trypsin digestion
and chemical degradation by CNBr. The addition of
trypsin should provide a short tetrapeptide, corre-
sponding to GstI[31–34] (sequence: LMER, see Fig-
ure 1) containing the rebuilt methionine. Conversely,
CNBr treatment leads to speciﬁc peptide bond cleav-
age on Met-X sites, with the concurrent production of
a C-terminal homoserinelattone moiety in place of
the original methionine. After trypsin treatment, the
FIGURE 2 HPLC analysis of the ligation reaction between the thioester (I) and the homoCys
derivative (II) at t ¼ 0 (solid line) and after 16 h (dashed line). The peak indicated by (*) is due to
the transthioesteriﬁcation of (I) with -Me. The peak indicated as (**) is due to the thiophenol.
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mixture was analyzed by LC–MS shown in the chro-
matogram reported in Figure 4A, where, as indicated,
the expected fragments were detected. For the tetra-
peptide LMER we determined an experimental MW
of 547.42 amu, in very good agreement with the
expected 547.28 amu value. The contextual MS/MS
fragmentation provided the sequence of the expected
tetrapeptide (see Supplementary Material S3). The
chemical cleavage by CNBr provided two main prod-
ucts with the expected MW (Figure 4B). The pres-
ence of the tryptic tetrapeptide and the expected frag-
mentation by CNBr strongly supported the fact that
methylation occurred only on the desired side chain
thiol of the homocysteine in position 32.
To produce the fully deprotected protein, treat-
ment with silver triﬂuoromethanesulfonate (AgOTf)/
HCl/DTT was carried out, bringing some changes to
the reported method of Tamamura et al.14
Following this procedure, we could not recover
any product; indeed, after the HCl/dimethylsulfoxide
(DMSO) treatment, we believe that most product was
still complexed to Ag+ ions, remaining trapped within
the AgCl precipitate. In this instance, DTT is particu-
larly useful, as it can also revert the oxidation of
methionines15 that typically occurs in this reaction.
Under the new conditions, the polypeptide was almost
quantitatively recovered in the DTT-containing frac-
tion, though in the reduced form. After protein puriﬁca-
tion, about 1.5 mg of pure ﬁnal product was recovered
and characterized by LC–MS, observing the expected
144 amu loss due to the Acm protections removal. The
ﬁnal product (V) had a shorter retention time compared
with the starting product (IV) (Figure 5A) and a purity
level higher than 90% by RP–HPLC. The experimental
MW (Figure 5B) was in very good agreement with the
theoretical value of 7388.31 amu (average MW) calcu-
lated assuming the cysteine in the reduced state.
CD Spectroscopy
A CD analysis of the fully reduced polypeptide in
phosphate buffer was carried out to determine the
FIGURE 3 (A) LC–MS monitoring of the methylation reaction on polypeptide (III). The reac-
tion is complete after 1 min. (B and C) The deconvoluted mass spectra of peaks at Rt 28.33 and
28.46 min are reported.
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global protein fold under these conditions and to per-
form a comparison with previous results obtained on
the recombinant protein. In Figure 6, a comparison of
spectra obtained on the full-length protein and on the
two precursor peptides is reported. As shown, the two
fragments displayed spectra characteristic of random
coils, with single minima at about 195 nm, while the
protein spectrum, though not ﬁtting any canonical
structure, exhibited a strong minimum at about 205 nm
and a second weak band at around 222 nm, indicative
of some higher conformational preferences of the full-
length polypeptide. Remarkably, within the 190–240 nm
spectral region, the CD curve of synthetic GstI[1–63]-
Gly is very similar to that reported by Napolitani et al.3
for the recombinant polypeptide, acquired under the
same buffer conditions, suggesting that they adopt very
similar, prevailingly -structure conformations. Indeed,
upon deconvolution of the CD curve, we found
the following composition of secondary structure: 
¼ 15.3%,  ¼ 60.7%, random coil ¼ 24.0%, that,
unless for a modest -helix contribution, is comparable
to that reported for the recombinant protein ( ¼ 0%;
FIGURE 4 (A) LC–MS analysis of the peptide mixture obtained following trypsin treatment of
the synthetic GstI[1–63]Gly-Cys(Acm40,47). Peptide fragments and MW are indicated. MW have
been calculated all as monoisotopic. MS/MS has also been carried out on the eluted peptides (see
Supplementary Material S3). (B) HPLC analysis of the mixture after CNBr treatment. Two main
products are detected with the MW expected by a splitting on the Met32-Glu33 bond and formation
of a homoserine lactone (HSL) moiety on the carboxyl side of the methionine.
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 ¼ 58.7%; coil ¼ 41.3%, see reference3). The entire
analysis has been carried on the reduced protein, as,
though cysteines oxidation status is currently not
known in vivo, they reportedly do not have any in-
volvement in GSII inhibition. Indeed, mutation of
Cys40 into alanines does not alter the protein activity
and mutation of Cys47 only slightly affects the GstI in-
hibitory activity.3 Furthermore, while Cys47 is con-
served between Rhizobium leguminosarum (Rl)-GstI
and Sinorhizobium meliloti (Sm)-GstI and Cys40 is
shifted in position, no cysteine residues are present in
Agrobacterium tumefaciens (At)-GstI, suggesting that,
if these proteins fulﬁll the same function,3 cysteines
should be reduced in (Rl)-GstI.
CONCLUSION
The chemical synthesis of the small protein GstI by
an NCL approach on a X-Met site is described in this
report. The synthesis has been successful, observing a
10% overall yield (0.2 moles over the 2 moles of
the starting thioester). Though the synthetic strategy
has already been described, the key steps of thiol
FIGURE 5 Acm removal reaction on product (IV) to obtain the ﬁnal protein (V). (A) An overlay
of chromatograms before and after treatment. (B) Deconvoluted mass spectrum relative to the main
peak. The polypeptide is in the reduced form.
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methylation and Acm removal have been optimized.
The ﬁnal protein, in the reduced form, has also been
preliminarly characterized by CD spectroscopy to
assess the presence of secondary structures. The mole-
cule is fully soluble and does not adopt canonical struc-
ture in aqueous buffers at neutral pH, but deconvolu-
tion of the CD curve has shown that the protein adopts
a prevailingly -structure conformation, according to a
previous report.3 These results suggest that the syn-
thetic protein, as obtained through this process, has
structural properties very similar to those described for
the recombinant protein.
EXPERIMENTAL
Materials
Fmoc-Gly-4-hydroxymethylphenoxyacetic (HMP)-derivat-
ized polystyrene resin (PS) and chlorotrytilchloride (Cl-TrtCl)
resins were purchased from NovaBiochem (Laufelﬁngen,
Switzerland). 9-Fluorenylmethoxycarbonyl (Fmoc)- or t-
Butyloxycarbonyl (t-Boc)–derivatized amino acids (purity
> 99%) and activating agents such as 1-H-Benzotriazolium,
1-[bis(dimethylamino)methylene]-hexaﬂuorophosphate(1-),
3-oxide (HBTU) and N-hydroxybenzotriazole (HOBt) were
from Inbios (Pozzuoli, Italy) and Novabiochem (Laufel-
ﬁngen, Switzerland). Fmoc-L-homoCys(Trt)-OH was from
Anaspec (San Jose, CA, USA). Synthesis-grade dichloro-
methane (DCM), dimethylformamide (DMF), methanol, tri-
ﬂuoroacetic acid (TFA), diethylether, and HPLC-grade
water and acetonitrile were from LabScan (Dublin, Ireland).
PyBOP was from Applied Biosystem (Foster City, CA,
USA). Reagents such as tri-isopropylsilane, ethyl sulphide,
thiophenol, methyl iodide, piperidine and DIEA were all
from Sigma–Aldrich (Milan, Italy). HPLC columns were
from Phenomenex (Torrance, CA, USA) and from Thermo-
Electron (Milan, Italy). The LC–MS systems equipped with
ESI sources were from ThermoElectron (Milan, Italy).
METHODS
Synthesis of GstI[1–63]-Gly by NCL. The C-terminal frag-
ment was prepared by automatic solid-phase synthesis
using a 433A Applied Biosystems automatic synthesizer
following the Fmoc methodology on a 100 moles scale.
20% Piperidine in DMF was used as Fmoc deprotecting
agent in all steps. Activation was performed using a 0.9
HBTU–HOBt and 2.0 DIEA molar excess over amino acid
(1.0 mmol). The C-terminal fragment was assembled from
Glu33 to Ser63 on an Fmoc–Gly–HMP resin (substitution
0.53 mmol/g) to avoid racemization of the C-terminal
amino acid, thus the resulting fragment GstI(33–63) con-
tained an additional C-terminal glycine. On the resulting
resin Fmoc-L-homoCys(Trt)-OH was coupled (1 h, RT)
using a ﬁvefold excess and PyBOP/DIEA (50% DCM/DMF
v/v) as activating agents. After Fmoc removal, the resin
was dried under vacuum. The fragment, homoCys32Met-
GstI[32–63]-Gly (polypeptide II) was cleaved using a
94:3:3 v/v/v TFA–H2O–tri-isopropylsilane (TIS) mixture
(2.0 mL/100 mg resin, 1.5 h reaction time at RT), precipi-
tated in cold ethyl ether (Et2O), and lyophilized from a 50%
H2O/CH3CN solution. 20 mg of crude polypeptide, were
again dissolved in 25% H2O/CH3CN containing 0.1% TFA
and 50 mM DTT, incubated at 378C for 2 h, and then puri-
ﬁed by RP–HPLC on a COMBI C18 5  2.1 cm ID column
(10 m, Phenomenex) using a gradient of CH3CN, 0.1%
TFA (Solvent B; Solvent A was H2O, 0.1% TFA) from 20
to 45% over 15 min (ﬂow 20 mL/min) and monitoring at
210 nm. Preparative puriﬁcations were carried out on a
LC8 Shimadzu HPLC system (Shimadzu Corporation, Mi-
lan, Italy). Fractions were characterized by LC–MS analy-
sis (0.2 g/fraction) to assess purity and molecular weight.
A LCQ DCA XP Ion Trap mass spectrometer (ThermoElec-
tron, Milan, Italy) equipped with an OPTON ESI source,
operating at 4.8 kV needle voltage and 3208C and with a
complete Surveyor HPLC system, comprising an MS pump,
an autosampler, and a photo diode array (PDA) was used. A
narrow bore 50  2 mm C18 Biobasic column, 300 A˚,
3 m (ThermoElectron) was used for these analyses, apply-
ing a gradient of CH3CN, 0.05% TFA (Solvent B) from 5 to
55% over a period of 40 min. The sample tray was kept at
208C, while the column was maintained at 258C. Solvent A
was H2O, 0.08% TFA. Mass spectra were continuously re-
corded in a mass interval of 400–2000 amu (normal mode)
and 1200–3500 amu (high mode), in positive modality
(hereafter, LC–MS conditions A). Multicharge spectra were
deconvoluted using the BioMass program implemented in
the Bioworks 3.1 package, provided by the spectrometer
manufacturer. Mass calibration was performed automati-
cally by means of selected multiple charged ions in the
presence of a calibrant (UltraMark, ThermoElectron). All
masses are reported as averaged values. Pure fractions were
pooled and lyophilized.
FIGURE 6 CD characterization of synthetic GstI[1–63]-
Gly. Spectra relative to the starting 1–31 and 32–63 poly-
peptides are also reported. Spectra have been recorded
between 260 and 190 nm.
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Synthesis of Fully Protected GstI[1–31]-COOH. The N-
terminal fragment GstI[1–31]-COOH was prepared by
automatic Fmoc chemistry, using a 433A Applied Biosys-
tems automatic synthesizer. The synthesis was carried out
on a chlorotritylchloride resin onto which the protected res-
idue Fmoc-Leu-OH was loaded using standard proce-
dures.16 Standard side chains protections compatible with
Fmoc chemistry were used throughout the synthesis for all
residues, except Cys40 and Cys47, which were introduced
as TFA-stable Acm derivatives. The N-terminal methionine
was introduced as Boc derivative. 20% Piperidine in DMF
was used as the Fmoc deprotecting agent in all steps. Acti-
vation was performed using a 0.9 HBTU–HOBt and 2.0
DIEA molar excess over amino acid (1.0 mmol). The
resulting protected polypeptide (630 mg) was removed
from the solid support by 1%TFA in DCM (v/v) treatments
(5 treatments of 10 mL, 2 min, RT); ﬁltrating in a 5% DIEA
in DCM solution (v/v), the solvent was evaporated and the
residual oil dried under vacuum at RT overnight. To charac-
terize the polypeptide, about 1 mg of product was treated
with 500 L of a 94:3:3 v/v/v TFA–H2O–TIS mixture for 1
h at RT, precipitated by adding cold Et2O and characterized
by LC–MS under the reported conditions A.
Preparation of the Fmoc-L-Cys-CONH2. To try to use a
odorless thiol instead of Et-SH for the preparation of C-ter-
minal thioesters, we prepared the cysteine derivative Fmoc-
L-Cys-CONH2. This reagent, which is particularly useful
also by virtue of the characteristic UV-absorption spectrum,
was prepared by solid-phase synthesis on 100 mol of
RINK amide resin, subst. 0.53 mmol/g. To this aim, the
resin was swollen in DCM–DMF 1:1 for 1 h, was exten-
sively treated with 20% piperidine in DMF to remove the
Fmoc protection, and then was washed thoroughly with
plenty of DMF. 500 mol of Fmoc-L-Cys(Trt)-OH was dis-
solved in 1.0 mL of DMF and poured onto the resin, then
1.0 mL of 0.5 M PyBOP in DCM and 1.0 mL of 2 M DIEA
in NMP were added and the suspension was mixed for 2 h
at RT. The amino acid was cleaved from the resin by treat-
ment with 3.0 mL of a 94:3:3 TFA–H2O–TIS v/v/v mixture
and puriﬁed by solid phase extraction on a manually packed
C18 cartridge. The amino acid was characterized by LC–
MS using a complete Surveyor HPLC system and an MSQ
single quadrupole mass spectrometer. The analysis was per-
formed on a Proteo C8 150  4.6 mm ID column (Phenom-
enex) using a gradient from 20 to 80% CH3CN, 0.1% TFA
over 35 min (ﬂow rate was 0.8 mL/min). Probe and cone of
the mass spectrometer were set at 3.0 kV and 35 V, respec-
tively, while the temperature was set at 3308C.
Preparation of the GstI[1–31] C-terminal Thioesters. Fully
protected GstI[1–31]-COOH was thioesteriﬁed with EtSH
(6-fold molar excess over the peptide12 or the odorless
Fmoc-L-Cys-CONH2 (6-fold molar excess). Reactions were
carried out in neat DCM at RT (5–16 h) using PyBOP (6-
fold molar excess over the peptide) and DIEA (12-fold
molar excess) as activating agents.12 The reactions were
monitored by removing small aliquots of solution, evapo-
rating the solvent, and performing the complete deprotec-
tion with a 94:3:3 v/v/v TFA–H2O–TIS mixture (500 L/
0.2 mL DCM solution, 1.5 h at RT). The resulting crude
material was then analyzed by LC–MS under the reported
LC–MS conditions A. When reactions were not completed,
further reagents were added until more than 90% conver-
sion was observed. The reaction mixtures were evaporated
and treated with a 94:3:3 v/v/v TFA–H2O–TIS mixture (3
mL/100 mg oil, 1.5 h at RT), and the crude products pre-
cipitated by adding cold Et2O and puriﬁed on a COMBI
C18 5  2.1 cm ID column (10 m, Phenomenex) applying
a gradient of Solvent B from 20 to 45% over 15 min (ﬂow
20 mL/min; 20 mg per run), monitoring at 210 nm. Purest
fractions were characterized by LC–MS analysis (0.2 g/
fraction, LC–MS condition A) identifying the products by
molecular mass determination.
Synthesis of GstI[1–31]-CO-S-(CH2)2-CO-Leu-COOH. This
thioester was directly prepared on a TAMPAL (trityl-asso-
ciated mercaptopropionic acid-leucine) resin.9–11 The resin
was prepared by coupling S-trityl mercaptopropionic acid
to Boc-Leu-Pam (HBTU/HOBt/DIEA) and was used after
removal of the trityl protecting group with two 1-min treat-
ments with 2.5% tri-isopropylsilane and 2.5% H2O in TFA.
The thioester bond was formed with the C-terminal Leu31
by using standard in situ–neutralization peptide-coupling
protocols for 1 h. Boc chemistry was accomplished using in
situ neutralization/HBTU activation procedure for all amino
acids.17 Commercially available Boc amino acids with clas-
sical protections were used throughout the synthesis. Each
synthetic cycle consisted of N-Boc removal by a 1- to
2-min treatment with neat TFA, a 1-min DMF ﬂow wash, a
10- to 20-min coupling time with 1.0 mmol of preactivated
Boc-amino acid in the presence of excess DIEA, and a sec-
ond DMF ﬂow wash. N-Boc-amino acids (1.1 mmol) were
preactivated for 3 min with 1.0 mmol of HBTU (0.50 M in
DMF) in the presence of excess DIEA (3 mmol). After cou-
pling of Gln residues, a DCM ﬂow wash was used before
and after deprotection by using TFA to prevent possible
high-temperature (TFA/DMF)–catalyzed pyrrolidone for-
mation. After chain assembly was completed, the peptide
was deprotected and cleaved from the resin by treatment
with anhydrous HF for 1 h at 08C with 5% p-cresol as scav-
enger. The peptide was precipitated with Et2O, dissolved in
aqueous acetonitrile, and lyophilized. The ﬁnal thioester
was puriﬁed by RP–HPLC on a COMBI C18 5  2.1 cm
ID column (10 m, Phenomenex) applying a gradient of
Solvent B from 20 to 45% over 15 min (ﬂow 20 mL/min,
20 mg per run), monitoring at 210 nm. Fractions were char-
acterized by LC–MS analysis (0.2 g/fraction, LC-MS con-
ditions A), assessing purity and molecular weight.
Preparation of homoCys32-GstI[1–
63]Gly-Cys(Acm)40,47 (III) by NCL
GstI[1–31]-CO-SEt or GstI[1–31]-CO-S(Fmoc-Cys-NH2)
or GstI[1–31]-CO-S-(CH2)2-CO-Leu-COOH (I) were
interchangeably used in ligation reactions. In a typical
experiment, 2 moles of a thioester were dissolved in
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2.0 mL sodium phosphate buffer 200 mM, guanidine
hydrochloride 6 M, pH 7.8. The solution was mixed with a
phosphate buffered solution (200 mM, guanidine hydro-
chloride 6 M, pH 7.8) of II (0.9 equiv of a 1.0 mM solu-
tion); 1% thiophenol (v/v) was directly added and then the
pH was checked to be * 7.4,6 The reactions were moni-
tored by RP–HPLC analysis for 16 h using a Jupiter 250 
4.6 mm ID RP-18 column (Phenomenex) operating at 1.0
mL/min. Aliquots of this solution were treated with equal
volumes of -Me for 30 min and then with 10% TCEP for
10 min to completely hydrolyze any thiol adduct before
RP–HPLC analysis. Peaks were collected and identiﬁed by
LC-MS analysis (conditions A). The ligated products were
puriﬁed using a Jupiter 25  1 cm ID RP18 column operat-
ing at 5 mL/min. Efﬂuents were monitored at 210 nm.
Fractions corresponding to the ligated product III were
pooled, characterized by LC–MS (conditions A), and ly-
ophilized. The ligation between (I) and Cys32-GstI[32–
63]-Gly was also carried out under the same conditions to
compare the reactivity of homocysteine with cysteine.
Alkylation of homoCys-containing
Polypeptides
Method A: Methylation with Methyl p-Nitro-benzene-
sulphonate (MpNBS)7. 0.7 mg of Product (III) were dis-
solved in 200 mM phosphate buffer, pH 8.6. To this solu-
tion 1.1 mg of MpNBS dissolved in CH3CN was added,
corresponding to a 50-fold excess over the thiol group. The
reaction was allowed to proceed for 1 h at RT and afterward
it was blocked by adding 25% TFA in water. The reagent
excess was removed by three subsequent extractions with
Et2O and the resulting product was characterized by LC–
MS under the reported conditions A.
Method B: Methylation with Methyl Iodide. The alkyla-
tion reaction with MeI ﬁrst was optimized on Cys-contain-
ing model peptides to avoid hyperalkylation. Reactions
were carried out by changing alkylating agent excess and
reaction time. The effects of reducing agents, like TCEP,
were also evaluated. Most experiments were performed
using the peptide LC1 that contained two cysteines
(sequence: CQSLLNSGMRC-NH2). Peptide aliquots of
0.25 mol (0.5 mol total thiols) were dissolved in 400 L
of 100 mM bicarbonate buffer, pH 8.3, and separately
treated with increasing molar excesses (10, 50, 100, 1000)
of MeI, always dissolved in 100 L DMF (5 mM peptide
ﬁnal concentration). Reactions were monitored by LC–MS
analysis following retention time and MW changes after 0,
1, 5, 15, and 30 minutes. To this aim, aliquots were re-
moved at the indicated times and the reactions quenched by
1 M DTT addition up to 250 mM ﬁnal concentration and
then TFA by bringing the pH to about 2. Polypeptide III
was alkylated with MeI to produce Met32-GstI[1–63]Gly-
Cys(Acm40,47) (IV) under the following conditions:
3.0 mg of polypeptide (about 0.15 mol) were dissolved in
2.0 mL of 100 mM bicarbonate buffer, pH 8.3, 5 mM
TCEP. The solution was left at RT for 10 min to allow
reduction of any disulphide, thereafter 100 L of 1.0 M
MeI in DMF was added and the solution was left to stand
for 1 min. 120 L of 1.0 M DTT was ﬁnally added and the
pH was brought to about 2 with pure TFA. The product IV
was puriﬁed by RP–HPLC using a Jupiter 25  1 cm ID
RP-18 column (Phenomenex) equilibrated with 5% solvent
B at 5 mL/min, monitoring at 210 nm. A gradient from 5 to
60% solvent B in 50 min was applied after injection and
elution of the low MW components. The purest fractions
were collected and analyzed by LC–MS under the reported
conditions A.
Proteolytic Digestions and Chemical
Fragmentation
The polypeptide IV (40 g) was dissolved in 30 L of 0.1
M Tris–Cl, pH 8.4, containing 20 mM CaCl2 and 10% ace-
tonitrile. 1-Chloro-3-tosylamido-4-phenyl-2-butanone–treated
trypsin was added at a ﬁnal enzyme-to-substrate ratio of 1:100
(w/w) and the mixture left at 378C for 5 h. CNBr fragmenta-
tion was performed in 70% formic acid according to
Gross.18,19
Tryptic and CNBr peptides were separated by means of
a modular CapLC system directly connected to the Z-spray
source of a Q-TOF Micro (Waters Corporation, Milford,
MA, USA). The sample (about 3 pmol), diluted at a concen-
tration of 1 pmol/L, was loaded onto a C18 precolumn (5
mm length  300 m ID) at a ﬂow rate of 20 L/min and
desalted for 5 min with a solution of 0.1% formic acid. The
sample was then directed onto a Symmetry-C18 analytical
column (10 cm  300 m ID) using 5% CH3CN, contain-
ing 0.1% formic acid at a ﬂow rate of 5 L/min, and eluted
increasing the CH3CN concentration. Electrospray MS and
MS/MS data were acquired on a Q-TOF Micro mass spec-
trometer ﬁtted with a Z-spray nanoﬂow electrospray ion
source. The mass spectrometer was operated in the positive
ion mode with a source temperature of 808C and with a
potential of 3000 V applied to the capillary probe. LC–MS
data of tryptic peptides were acquired with the instrument
operating in data directed analysis (DDA) MS/MS mode.
The MS/MS data were processed automatically, and de
novo sequencing was obtained by means of ProteinLynx
Global Server 2.0.
Acm Removal
Acm was removed from the polypeptide by successive
treatments with AgOTf14 and 1 M DTT/aqueous 1 M HCl.
Brieﬂy, the polypeptide (0.25 mol, ca. 2 mg) was dis-
solved in a solution (200 L) of 1.5% (v/v) anisole in TFA.
A 40-fold molar excess of AgOTf then was added and the
reaction was left to proceed for 1.5 h at 48C. Dry Et2O was
added to the reaction to afford powder. After being washed
three times with Et2O the product was left overnight at 48C.
Afterward, it was treated with 50% 1.0 M DTT/1 M HCl at
RT for 4 h and, after removal of AgCl precipitate by ﬁltra-
tion, the ﬁltrates were diluted in H2O and then characterized
by LC–MS using the described method. Final products
were ﬁnally puriﬁed by RP–HPLC under the conditions
described in the previous section.
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CD Spectroscopy
CD experiments were carried out on a J-715 Jasco spectro-
polarimeter using a 0.1 cm path length quartz cuvette. A
phosphate (10 mM, pH 7.0) buffered solution of protein
(1  105 M) was used to record spectra between 260 and
190 nm. The instrument was calibrated with an aqueous so-
lution of D-10-(+)-camphorsulphonic acid20 at 290 nm.
Three spectra for each sample were recorded, averaged, and
transformed in molar ellipticity/residue, []. CD spectra
were recorded with a time constant of 4 s, a 2 nm band-
width, and a scan rate of 5 nm/min, were signal averaged
over at least ﬁve scans, and were baseline corrected by sub-
tracting a buffer spectrum. The spectrum of GstI[1–63]-Gly
was deconvoluted using the CD Spectra Deconvolution
software, version 2.1.21
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Abstract: An overview of the applications of N?-(1-phenyl-2-mercaptoethyl) auxiliary is presented. We describe the on
resin preparation (C?-carboxy and thioester) of N?-auxiliary derivatives of glycine and the synthesis and incorporation of
preformed N?-auxiliary derivatives of glycine and alanine with the protection schemes, including the thiazolidine strategy
for SPPS. Such approaches allowed the synthesis of the protein cytochrome b562 as well as native circular peptides after
successful removal of the auxiliary.
Keywords: native chemical ligation, peptide cyclization, auxiliary group, protecting group.
INTRODUCTION
During the last decade, total chemical synthesis has been
established as the most rapid and efficient way to chemically
gain access to small and proteins 1]. Up to the present, many
ligation chemistries have been developed [2]. However,
Native Chemical Ligation (NCL) [3] has been demonstrated
to be uniquely effective. In the NCL scheme, a C-terminal
thioester fragment reacts chemoselectively with an N-
terminal cysteine peptide in aqueous solution at neutral pH.
In the first step of the reaction, transthioesterification takes
place by thiol exchange between the free thiol of the N-
terminal cysteine and the thioester moiety on the other
peptide. The newly generated thioester then undergoes an S
to N acyl shift due to the proximity of the amino group to the
thioester functionality, thus generating a native amide bond
at the ligation site. NCL has also been used to generate
cyclic peptides via an intramolecular reaction [4]. The
requirement for cysteine at the site of peptide ligation is an
intrinsic restriction of the standard NCL strategy. In proteins,
Cys occurs with relatively low frequency; many proteins do
not have suitably-disposed cysteines for the NCL strategy
and some proteins lack Cys residues entirely. Thus,
continuing demand for large polypeptides and proteins has to
the development of removable auxiliary groups to extend the
applicability of NCL to ligation and cyclization of
unprotected peptides in aqueous solution at an X-X site
(where X= any amino acid) [5]. In this paper, an exhaustive
description of N?-(1-phenyl-2-mercaptoethyl)-based [6]
auxiliaries will be given, including synthetic strategies (on
resin derivatization and synthesis of the preformed amino
acids ready to be used in SPPS) and applications in both
intermolecular (ligation) and intramolecular (cyclization)
reactions.
*Address correspondence to this author at the Department of Structural
Biology and Bioinformatics, University of Geneva, 1 rue Michel Servet,
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DEVELOPMENT OF N?-(1-PHENYL-2-MERCAPTO-
ETHYL) AUXILIARIES.
The first extension of NCL was presented by Canne et al
[5a], who exploited two acid-stable N?-thiol containing
auxiliaries, designed to mimic the side-chain of a native
cysteine. The reductively cleavable N?-(oxyethanethiol) 1
that has a 1,3-aminothiol structure, showed a relatively slow
amide formation rate while the N?-(2-mercaptoethyl) 2,
which was not designed to be cleavable, showed superior
rearrangement rates (Scheme 1).
Scheme 1. Different auxiliary groups.
 The interesting propensity of the latter toward a faster
ligation prompted us to design novel auxiliary groups that
could take advantage of the superior ligation rates of 2 and
allow its facile and complete removal after ligation.
A case in point is the N?-(1-phenyl-2-mercaptoethyl)
auxiliary [6a-c] 3, which combines the faster ligation rate of
the N?–(2-mercaptoethyl) group through a five-membered
ring intermediate, enabling at the same time its complete
removal after ligation. Indeed, the introduction of a 1-phenyl
group on the N?-(2-mercaptoethyl) template generates a
benzylamine derivative that is completely stable under the
strong acidic conditions used in SPPS to cleave peptide-
resins (HF or TFA) making the auxiliary group compatible
with both Boc- and Fmoc-based chemistries. Furthermore,
because of the S to N acyl shift intrinsic to the mechanism of
NCL, benzylamine to benzylamide conversion occurs during
the reaction making the auxiliary readily cleavable under
similar or milder conditions originally required for the
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cleavage of the peptide (Scheme 2 ). In order to
unambiguously monitor reaction progress (proof of the
amide bond formation) and to distinguish between the
rearranged and unrearranged products that posses same
mass, a sample of the ligation mixture must be treated with
an excess of 2-mercaptoethanol. Indeed, the newly added
mercaptan is necessary to intercept any unrearranged
thiolactone, thus generating, in case of unrearranged
material, a new specie with characteristic mass and HPLC
retention time. Finally, since the auxiliary can be cleaved
only when is linked to an amide group (benzylamines are
stable to strong acidic conditions), its removal proves that
the product is the desired material.
PREPARATION OF N-TERMINAL GLYCINE N?-(1-
PHENYL-2-MERCAPTOETHYL) PEPTIDES VIA ON-
RESIN BROMIDE DISPLACEMENT
Our original scheme relied on the reaction of the
appropriate benzylamine with an N-terminal bromo-
acetylated peptide on a solid support (Scheme 3). Two
different benzylamine derivatives were synthesized [6b]: 1-
(4-methoxyphenyl)-2-(4-methylbenzylthio)-ethylamine 4
and 1-(2,4-dimethoxyphenyl)-2-(4-methylbenzylthio)-ethyl-
amine 5.
Both amine precursors, 4 and 5, were easily synthesized
in three steps from the bromoacetophenone derivative of
choice. Finally, reaction of such amines with a resin-bound
bromoacetyl-peptide generated, after cleavage/deprotection
steps, the desired N?-(1-phenyl-2-mercaptoethyl) peptides.
N-terminal glycine model peptides of identical sequence
bearing either a mono or dimethoxy phenyl substituted N?-
(1-phenyl-2-mercaptoethy) auxiliary were reacted with the
same peptide thioester fragment to evaluate both the ligation
and deprotection steps. While the removal of the auxiliary
from both products was accomplished in quantitative way,
the l igation involving N?-1-(4-methoxyphenyl)-2-
mercaptoethyl auxiliary showed superior yield [6b] thus
directing our focus on the mono-methoxy phenyl-substituted
analogue for further development. After the preliminary
work on model peptides which focused on the optimization
of ligation conditions and auxiliary cleavage, we attempted
the total chemical synthesis of cytochrome b562, a
functional protein with no cysteine residues [6c] . In such a
Scheme 2. Native Chemical Ligation and extended Chemical Ligation.
Scheme 3. On-resin auxiliary formation.
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synthesis (Figure 1), the C-terminal portion of cytochrome
b652 (64-106) was prepared using 1-(4-methoxyphenyl)-2-
(4’-methylbenzylthio)-ethylamine 4 via SN2 displacement of
the highly activated bromide from the N-terminal
bromoacetyl peptide on a solid support.
Two variants of the N-terminal portion were synthesized.
These include cytochrome b562 (1-63) with either Met or
SeMet at position 7, both obtained as thioester fragments
ready for use in ligation reactions. Both of the ligations were
completed after overnight incubation. Upon auxiliary
removal via HF treatment, both proteins were properly
folded in the presence of the corresponding heme group.
CYCLIZATION REACTION
The on-resin incorporation of the auxiliary moiety via
SN2 displacement of the bromide from a N-terminal
bromoacetyl peptide has also been applied to the synthesis of
circular peptides via an intramolecular reaction of linear
precursors having both reactive species, the thioester and the
1,2 amino-thiol moieties, on the same molecule [6d]. Since
thioesters are known to be susceptible to aminolysis, a
possible side reaction could be the loss of peptide due to a
large excess of the incoming primary amine. The reaction
has to be conducted using a minimal excess (1.1 equiv.) of
amine 4 in the presence of 1.5 equiv. of base (DIEA).
Under such controlled conditions, no detectable loss of
resin weight was observed after overnight incubation at room
temperature. After the cleavage/deprotection step, the
desired cyclic peptide was obtained using thiophenol as
catalyst. Several experiments were carried out to optimize
cyclization conditions, and the most critical parameter was
pH precisely set to 7.4. Finally, the subsequent facile
removal of the auxiliary group yielded the desired cyclic
peptide with native structure.
PREPARATION OF N-TERMINAL N?-(1-PHENYL-2-
M E R C A P T O E T H Y L )  P E P T I D E S  U S I N G
PREFORMED N?-(1-PHENYL-2-MERCAPTOETHYL)
AMINO ACIDS
The former strategy, although successfully applied in
both inter- and intramolecular reactions at the glycine site,
presents a few limitations. Indeed, the on-resin preparation
of peptide segments featuring a substituted residue at the N-
terminus may generate a side product on the 2-bromoacetyl
residue precursor through an elimination mechanism [5a].
Such phenomenon can be further complicated either by the
size of the desired peptide (especially with large fragments
due to incomplete acyclation reactions) or by the type of
resin (C?-thioester resin), which can be susceptible to
aminolysis/hydrolysis depending on the conditions. We
realized that incorporation of the auxiliary group into a
peptide chain (especially on long peptides) through on-resin
bromine displacement could limit the real usefulness of the
auxiliary group. Therefore we set out to synthesize amino
acid derivatives incorporating the auxiliary moiety ready to
be coupled in SPPS (Scheme 4).
Based on such premises, we designed a simple synthetic
strategy to obtain N?-(1-phenyl-2-mercaptoethyl) amino
acids ready to be incorporated into any C?-functionalized
peptide resin. Thus, we prepared an auxiliary derivatized
glycine and alanine. Alanine was selected for its high
abundance in proteins and small side-chain.
Importantly, our synthetic strategy [6f], which is based
on the reductive amination step (Scheme 5), allows the direct
Figure 1. Synthesis of Cytochrome b562.
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conjugation of an amino acid with the auxiliary template. It
is interesting to remark that such a reaction generates a new
stereogenic center at the former carbonyl of the auxiliary
skeleton when optically pure amino acids (e.g., alanine) are
used. The two resulting diastereomers can be separated and
individually evaluated for the ligation or cyclization
reactions. Consequently, using such a synthetic scheme, we
have been able to synthesize the N?-unprotected derivative 5,
the diastereomers 6a and 6b, the acid-labile protected Boc-
N?(Aux)-Gly-OH 7 and Boc-N?(Aux)-Ala-OH 8b and the
base-labile Fmoc-N?(Aux)-Gly-OH 9 and Fmoc-N?(Aux)-
Ala-OH 10b (Scheme 5).
COUPLING USING OF PROTECTED OR
UNPROTECTED N?- (1-PHENYL-2-MERCAPTO-
ETHYL) AMINO ACIDS
The coupling of N?-unprotected derivatives 5, 6a and 6b
requires the use of 1.1 equiv. of activated amino acid to
avoid the generation of oligomerized side products. Under
such controlled conditions, all unprotected derivatives 5, 6a
and 6b were successfully coupled to a model peptide C?-
thioester.
Boc-protected derivatives were also readily coupled to
the peptide resin. However, they cannot be used due to the
TFA mediated cleavage of the auxiliary group, which
probably takes place prior or concomitantly to the Boc group
deprotection. Indeed, stability tests carried out in solution on
Boc-N?(Aux)-Gly-OH 7 with different percentages of TFA
in DCM showed that the Boc-protected amino acid is
extremely sensitive to acidic conditions. Even at TFA
concentrations as low as 5%, both the auxiliary and the Boc
groups were completely cleaved in 30 minutes.
Consequently, we turned our attention to a base-labile
protection strategy. To be compatible with both ligation and
cyclization strategies, a suitable protecting group must be
safely removed from a C?-thioester peptide. Recently
Clippingdale et al. [7] reported the use of DBU for the
synthesis of peptide C?-thioesters via Fmoc-based chemistry.
Although such methodology is applicable only to the
preparation of small peptides, its use in a single step presents
practically no side reactions.
Thus, the Fmoc-N?(Aux)-Ala-OH compound 10b was
successfully coupled to a peptide resin C?-thioester and the
Fmoc group was removed using 1% DBU in anhydrous
DMF. No appreciable amount of resin was lost during the
Fmoc deprotection step. The desired peptide was obtained
after standard HF cleavage.
THIAZOLIDINE PROTECTION SCHEME
Thiazolidine derivatives have been successfully used to
protect the N-terminal ?-aminothiol moiety of cysteine
during syntheses of peptides [8]. Furthermore, such
structures have been exploited as N-terminal protection for
cysteine in the multi-fragment synthesis of different natively
folded proteins [9,10]. Accordingly, in ligation strategies
involving three or more peptide fragments, the 1,2-
aminothiol of the N-terminal (Aux)-middle segment must be
protected to avoid cyclization [6d-11] or polymerization. To
this end, the thiazolidine structure provides a convenient
temporary protection for the N-terminal Cys residue for
peptide segments containing a C-terminal thioester. During
the ligation reaction the thiazolidine group effectively blocks
the 1,2 aminothiol moiety of the N-terminal cysteine thus
preventing cyclization or polymerization.
Our aim was to take advantage of the secondary amine of
the 1,2 aminothiol moiety of our auxiliary group to prepare
SPPS-ready N?(Aux)-amino, which could be also suitable
for the multi-fragment ligation strategy. A case in point was
the thiazolidine formation with the secondary amine and the
thiol groups of the N?(Aux)-derivatized amino acid that
generates a convenient temporary tertiary amine, suitable for
SPPS. We thus prepared the thiazolidine derivatives 11 and
diastereomers 1 2 a  and 12b (Scheme 5 ), which were
conveniently obtained from their precursors 5, 6a and 6b in a
two-step procedure [6f]. The thiazolidine 11 was coupled to
a model peptide made by Fmoc chemistry. Analysis of the
Scheme 4. Application of preformed Na-(1-phenyl-2-mercaptoethyl) amino acid.
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crude material after TFA cleavage showed no traces of ring
opening (Scheme 6).
Finally, the free 1,2-aminothiol group of the N-terminal
auxiliary-derived glycinyl peptide was produced by
treatment with O-methylhydroxylamine under acidic
conditions (identical to those reported for N-terminal
cysteine derivatives) in the post cleavage mixture [8-10].
Future work will present a more exhaustive study on
thiazolidine derivatives including the use of alanine
derivatives in SPPS and the exploitation of such protection
scheme in Boc chemistry.
CYCLIZATION STUDIES USING N?(AUX)-AA-OH
DERIVATIVES.
The coupling of Gly derivative 5 to a model peptide of
sequence GSYRFG on a thioester resin yielded fragment
G(Aux)-GSYRFG-C?OSR, which quantitatively cyclized in
0.5 h under standard conditions. Subsequent removal of the
auxiliary group by HF treatment provided the native peptide
as a single peak by HPLC. The two Ala-based diastereomers,
6a and 6 b, were also coupled to the same model peptide
GSYRFG-C?OS-resin. After HF cleavage, each peptide was
purified by HPLC. Both linear purified peptide
diastereomers, A(Aux)-GSYRFG-C?OSR derived from 6 a
and 6b, were cyclized as before affording each one a mixture
of two cyclic compounds with the same mass (with superior
conversion for peptide diastereomer derived from 6a). These
results suggest epimerization at the chiral center of the
alanine residue.
HPLC analysis of the crude reactions after TFA removal
of the auxiliary group in both cases still showed the presence
of two peaks with the same mass corresponding to the
cyclized peptide without the auxiliary group. Evaluation of
the epimerization ratios were done by comparison to the D-
and L-Ala cyclic peptides (AGSYRFG) synthesized on an
oxime resin [12]. The results showed 15% and 30%
epimerization of the Ala residue for the peptides derived
from 6 a  and 6b,  respectively. Such high extent of
racemization (especially for the diastereomer 6b) could not
come from hydrolysis of the ester due to the different 1H-
NMR spectrum and HPLC retention time of the two
diastereomers [6f]. Since reductive amination has widely
been used in peptide chemistry for the preparation of N-
alkykated amino acids [13] and is known to give no or little
epimerization [14], we set out to determine whether the
major source of epimerization resulted from the coupling or
from the cyclization step.
Determination of the epimerization step was
accomplished by detailed HPLC analysis of both the linear
precursors and the cyclization products. Indeed, whereas
both linear precursors showed a single symmetrical peak on
a C-8 column, a non-symmetrical shape was obtained on a
C-18 column. Thus, when the A(aux)-GSYRFG
diastereomer derived from 6a was repurified on a C-18
Scheme 5. N?-(1-phenyl-2-mercaptoethyl) amino acids.
Scheme 6. Thiazolidine protection scheme.
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column, the cyclization reaction produced only one peak
with the expected mass for the cyclized material (Figure 2).
Finally, our synthetic efforts to synthesize and separate
amino acids 6a  and 6b  were validated by the different
reactivities of these Ala derivatives during the coupling
(epimerization ratios) steps. Unfortunately, our preliminary
efforts to reduce the extent of epimerization by using
carbodiimide mediated coupling (DCC) with alternatively
HOBt or HOOBt (3-hydroxy-3,4-dihydro-4-oxo-1,2,3-
benzotriazine) as activating agent failed. Similar
epimerization results were also obtained when the Fmoc-Ala
derivative 9b was employed.
WORK DONE BY OTHERS
Other groups have also contributed to the exploitation of
the N?-(1-phenyl-2-mercaptoethyl) auxiliary groups. The
work presented by Marinzi et al. [15] described the scaffold-
mediated amide bond formation, but it did not address how
to remove the auxiliary group after the ligation step. An
interesting photo-removable version of this auxiliary group
has been also presented by Kawakami et al. [16] and later by
Marinzi et al. [17]. More recently, Clive et al. [18] has
described the synthesis of different N?-auxiliary amino acid
templates although they were not used in SPPS.
CONCLUSION
Our work has broadened the application of Native
Chemical Ligation (NCL) by extending the number of
available ligation sites. Using the Extended Chemical
Ligation (ECL) strategy at X-Gly sites, we have readily
synthesized and folded cytochrome b562, a functional
protein devoid of cysteine residues. This method diminished
the sequence depending restrictions imposed by NCL. The
same methodology has also been applied to an
intramolecular reaction, thus facilitating the chemical
synthesis of cyclic peptides from linear unprotected
precursors. We have also made available the preformed
auxiliary derivatized alanine and glycine residues ready for
SPPS. This makes our technology suitable for both ligation
and cyclization of unprotected peptide segments and even
more sequence independent. Future work will focus on
trying to find different coupling reagents and/or conditions
that eliminate or reduce epimerization of the N?-(Aux)-Ala
derivatives during SPPS.
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